microRNA information: hsa-miR-125b-5p
Section | ID | link |
---|---|---|
Mature name: | hsa-miR-125b-5p | miRbase |
Accession: | MIMAT0000423 | miRbase |
Precursor name: | hsa-mir-125b-1 | miRbase |
Precursor accession: | MI0000446 | miRbase |
Symbol: | MIR125B1 | HGNC |
RefSeq ID: | NR_029671 | GenBank |
Sequence: | UCCCUGAGACCCUAACUUGUGA |
Reported expression in cancers: hsa-miR-125b-5p
miRNA | cancer | regulation | reporting | PUBMED | method |
---|---|---|---|---|---|
hsa-miR-125b-5p | acute myeloid leukemia | upregulation | "Myeloid cell differentiation arrest by miR 125b 1 ......" | 18936236 | |
hsa-miR-125b-5p | acute myeloid leukemia | upregulation | "This paper evaluated the association between micro ......" | 25646775 | RNA-Seq |
hsa-miR-125b-5p | bladder cancer | downregulation | "We identified a subset of 7 miRNAs miR-145 miR-30a ......" | 19378336 | qPCR |
hsa-miR-125b-5p | bladder cancer | downregulation | "microRNA-125b miR-125b was implicated to have clos ......" | 20549700 | |
hsa-miR-125b-5p | bladder cancer | downregulation | "In the first - discovery - phase microarray cards ......" | 27468885 | Microarray; qPCR |
hsa-miR-125b-5p | breast cancer | downregulation | "MiR-125b is one of the known down-regulated miRNAs ......" | 20978686 | |
hsa-miR-125b-5p | breast cancer | downregulation | "The microRNA miR-125b is dysregulated in various h ......" | 21444677 | |
hsa-miR-125b-5p | breast cancer | downregulation | "To compare the carcinogenic process in tumors with ......" | 24810926 | qPCR |
hsa-miR-125b-5p | breast cancer | downregulation | "Dysregulated miR-125 observed in multiple cancer t ......" | 26782438 | qPCR |
hsa-miR-125b-5p | breast cancer | downregulation | "Among the differentially expressed miRNAs in breas ......" | 27226726 | |
hsa-miR-125b-5p | breast cancer | downregulation | "Downregulation of miR-125b-1 is associated with po ......" | 27386402 | |
hsa-miR-125b-5p | cervical and endocervical cancer | upregulation | "OCT4 induces upregulation of miR-125b through dire ......" | 23928699 | |
hsa-miR-125b-5p | colorectal cancer | downregulation | "MicroRNA miR 125b is a prognostic marker in human ......" | 21399871 | qPCR |
hsa-miR-125b-5p | colorectal cancer | downregulation | "The study was divided into two phases: firstly qRT ......" | 25255814 | qPCR; Microarray |
hsa-miR-125b-5p | colorectal cancer | downregulation | "The expression levels of the two miRNAs were deter ......" | 26693202 | Reverse transcription PCR; qPCR |
hsa-miR-125b-5p | colorectal cancer | downregulation | "Screening miRNAs for early diagnosis of colorectal ......" | 27022275 | RNA-Seq |
hsa-miR-125b-5p | esophageal cancer | downregulation | "HPV 16 E6 promotes cell growth of esophageal cance ......" | 26722596 | |
hsa-miR-125b-5p | gastric cancer | deregulation | "miRNA expression signature was first analyzed by r ......" | 21628394 | qPCR |
hsa-miR-125b-5p | gastric cancer | downregulation | "In this study we found that the expression levels ......" | 26504803 | |
hsa-miR-125b-5p | gastric cancer | upregulation | "Here we investigate the role of miR-125b in gastri ......" | 27220320 | |
hsa-miR-125b-5p | glioblastoma | upregulation | "Accumulating evidence indicates that microRNA miR- ......" | 23857508 | |
hsa-miR-125b-5p | head and neck cancer | downregulation | "To identify miRNAs associated with head and neck s ......" | 23416980 | |
hsa-miR-125b-5p | head and neck cancer | downregulation | "Conversely decreased expressions of miR-153 miR-20 ......" | 25677760 | |
hsa-miR-125b-5p | kidney renal cell cancer | deregulation | "This study aims to profile dysregulated microRNA m ......" | 25938468 | Microarray |
hsa-miR-125b-5p | liver cancer | downregulation | "In this study we demonstrated the down-regulation ......" | 22942733 | Northern blot; qPCR |
hsa-miR-125b-5p | liver cancer | downregulation | "We have previously reported frequent down-regulati ......" | 22991213 | |
hsa-miR-125b-5p | liver cancer | downregulation | "ERManI is a target of miR 125b and promotes transf ......" | 23940818 | Microarray |
hsa-miR-125b-5p | liver cancer | downregulation | "This study investigates the involvement of miR-125 ......" | 24811246 | qPCR |
hsa-miR-125b-5p | liver cancer | downregulation | "Among these miRNAs miR-125b expression was most st ......" | 25953743 | |
hsa-miR-125b-5p | lung cancer | upregulation | "Notably ectopic expression of miR-125b led to the ......" | 26351908 | |
hsa-miR-125b-5p | lung squamous cell cancer | downregulation | "Circulating miR 125b is a novel biomarker for scre ......" | 22806310 | Reverse transcription PCR |
hsa-miR-125b-5p | melanoma | downregulation | "Downregulation of miR 125b in metastatic cutaneous ......" | 20827223 | Microarray; Reverse transcription PCR |
hsa-miR-125b-5p | melanoma | downregulation | "In a previous study we found that the expression o ......" | 21460750 | |
hsa-miR-125b-5p | ovarian cancer | downregulation | "miR-125b has essential roles in coordinating tumor ......" | 25944662 | |
hsa-miR-125b-5p | ovarian cancer | downregulation | "miRNA mimics and miRNA inhibitors were used in qua ......" | 26646586 | qPCR |
hsa-miR-125b-5p | prostate cancer | upregulation | "Our previous studies demonstrated that in human pr ......" | 23585871 | |
hsa-miR-125b-5p | sarcoma | downregulation | "This study is aimed to investigate the clinical im ......" | 26330295 | qPCR |
hsa-miR-125b-5p | sarcoma | downregulation | "We report miR-125b was downregulated in both chond ......" | 26966351 | |
hsa-miR-125b-5p | sarcoma | downregulation | "The expression of miR-125b in human chondrosarcoma ......" | 27576314 | qPCR |
Reported cancer pathway affected by hsa-miR-125b-5p
miRNA | cancer | pathway | reporting | PUBMED | functional study |
---|---|---|---|---|---|
hsa-miR-125b-5p | bladder cancer | Apoptosis pathway | "Hsa miR 125b suppresses bladder cancer development ......" | 24396870 | |
hsa-miR-125b-5p | bladder cancer | Apoptosis pathway | "Hsa miR 125b suppresses bladder cancer development ......" | 24512851 | |
hsa-miR-125b-5p | bladder cancer | cell cycle pathway | "MicroRNAs miRNAs are small non-coding RNAs 18-25 n ......" | 26807182 | Colony formation; Luciferase; Western blot |
hsa-miR-125b-5p | breast cancer | Apoptosis pathway | "In this study we utilized a miRNA array to compare ......" | 20460378 | |
hsa-miR-125b-5p | breast cancer | cell cycle pathway | "miR 125b is methylated and functions as a tumor su ......" | 21444677 | |
hsa-miR-125b-5p | breast cancer | Apoptosis pathway | "Functional cooperation of miR 125a miR 125b and mi ......" | 23519125 | |
hsa-miR-125b-5p | breast cancer | Epithelial mesenchymal transition pathway | "miR 125b regulates side population in breast cance ......" | 23606360 | |
hsa-miR-125b-5p | breast cancer | cell cycle pathway | "miR 125b acts as a tumor suppressor in breast tumo ......" | 24098452 | |
hsa-miR-125b-5p | breast cancer | Epithelial mesenchymal transition pathway | "MiR 125b regulates epithelial mesenchymal transiti ......" | 25605244 | |
hsa-miR-125b-5p | breast cancer | Apoptosis pathway | "The role of miR 125b mitochondria caspase 3 pathwa ......" | 25894378 | Luciferase |
hsa-miR-125b-5p | breast cancer | cell cycle pathway | "We demonstrate that resveratrol regulates apoptoti ......" | 26890143 | |
hsa-miR-125b-5p | breast cancer | Epithelial mesenchymal transition pathway | "miR 125b inhibited epithelial mesenchymal transiti ......" | 27226726 | |
hsa-miR-125b-5p | cervical and endocervical cancer | Apoptosis pathway; mTOR signaling pathway | "MiR 125b inhibits tumor growth and promotes apopto ......" | 23160634 | Flow cytometry; MTT assay |
hsa-miR-125b-5p | cervical and endocervical cancer | Apoptosis pathway | "OCT4 induces upregulation of miR-125b through dire ......" | 23928699 | Luciferase |
hsa-miR-125b-5p | cervical and endocervical cancer | Apoptosis pathway | "MicroRNAs as biomarkers of cervical cancer develop ......" | 24402874 | |
hsa-miR-125b-5p | gastric cancer | cell cycle pathway; Apoptosis pathway | "Expression profiling and functional analysis of hs ......" | 24846940 | |
hsa-miR-125b-5p | gastric cancer | Apoptosis pathway | "miR 125b Suppresses Proliferation and Invasion by ......" | 26504803 | |
hsa-miR-125b-5p | glioblastoma | Apoptosis pathway | "MiR 125b acts as an oncogene in glioblastoma cells ......" | 24169356 | Colony formation; Luciferase; Western blot |
hsa-miR-125b-5p | glioblastoma | cell cycle pathway | "miR 125b promotes cell proliferation by directly t ......" | 24356103 | |
hsa-miR-125b-5p | glioblastoma | Apoptosis pathway | "miR 125b inhibitor enhance the chemosensitivity of ......" | 24643683 | |
hsa-miR-125b-5p | glioblastoma | Apoptosis pathway; cell cycle pathway | "miR 125b controls apoptosis and temozolomide resis ......" | 24901050 | |
hsa-miR-125b-5p | head and neck cancer | cell cycle pathway | "A global miRNA profiling was done on 51 formalin-f ......" | 20145181 | Flow cytometry |
hsa-miR-125b-5p | liver cancer | cell cycle pathway | "Our previous study showed that miR-125b was a prog ......" | 20827722 | |
hsa-miR-125b-5p | liver cancer | cell cycle pathway | "In this study we demonstrated the down-regulation ......" | 22942733 | |
hsa-miR-125b-5p | liver cancer | cell cycle pathway | "Sirtuin7 oncogenic potential in human hepatocellul ......" | 23079745 | |
hsa-miR-125b-5p | lung cancer | Epithelial mesenchymal transition pathway | "Up regulation of miR 125b reverses epithelial mese ......" | 26351908 | |
hsa-miR-125b-5p | lung cancer | Epithelial mesenchymal transition pathway | "Retraction Note to the article "Up regulation of m ......" | 26356362 | |
hsa-miR-125b-5p | lymphoma | Apoptosis pathway | "Aberrant expression of oncogenic miRNAs including ......" | 24479800 | |
hsa-miR-125b-5p | melanoma | Apoptosis pathway | "MicroRNA miR 125b induces senescence in human mela ......" | 21460750 | |
hsa-miR-125b-5p | melanoma | cell cycle pathway | "miR 125b induces cellular senescence in malignant ......" | 24762088 | Western blot; Flow cytometry |
hsa-miR-125b-5p | melanoma | Epithelial mesenchymal transition pathway | "Here we used in silico analysis of microRNA expres ......" | 26968260 | |
hsa-miR-125b-5p | ovarian cancer | cell cycle pathway | "MiR 125b targets BCL3 and suppresses ovarian cance ......" | 20658525 | |
hsa-miR-125b-5p | ovarian cancer | Apoptosis pathway | "miR 125b confers resistance of ovarian cancer cell ......" | 21823019 | Flow cytometry; Western blot; Luciferase |
hsa-miR-125b-5p | ovarian cancer | Apoptosis pathway | "miRNA mimics and miRNA inhibitors were used in qua ......" | 26646586 | Western blot; Luciferase |
hsa-miR-125b-5p | ovarian cancer | Epithelial mesenchymal transition pathway | "MicroRNA-125b miR-125b is overexpressed in several ......" | 27383536 | Western blot; Luciferase |
hsa-miR-125b-5p | prostate cancer | Apoptosis pathway | "Oncomir miR 125b suppresses p14ARF to modulate p53 ......" | 23585871 | |
hsa-miR-125b-5p | retinoblastoma | cell cycle pathway | "Among them hsa-miR-373 hsa-miR-125b and hsa-miR-18 ......" | 26730174 | |
hsa-miR-125b-5p | retinoblastoma | Apoptosis pathway | "The miRNA miR-125b is dysregulated in various huma ......" | 27518550 | Luciferase |
hsa-miR-125b-5p | sarcoma | cell cycle pathway; Apoptosis pathway; mTOR signaling pathway | "MiR 125b inhibits cell biological progression of E ......" | 24517182 | Western blot |
Reported cancer prognosis affected by hsa-miR-125b-5p
miRNA | cancer | prognosis | reporting | PUBMED | functional study |
---|---|---|---|---|---|
hsa-miR-125b-5p | B cell lymphoma | drug resistance; progression; recurrence; worse prognosis; poor survival | "Then from eight potential drug-resistant miRNAs wh ......" | 26870228 | |
hsa-miR-125b-5p | acute myeloid leukemia | differentiation | "Myeloid cell differentiation arrest by miR 125b 1 ......" | 18936236 | |
hsa-miR-125b-5p | bladder cancer | differentiation; tumorigenesis | "microRNA-125b miR-125b was implicated to have clos ......" | 20549700 | Luciferase |
hsa-miR-125b-5p | bladder cancer | cell migration; metastasis | "The expression of microRNA-125b miR-125b has been ......" | 23425975 | Western blot; Luciferase |
hsa-miR-125b-5p | bladder cancer | malignant trasformation | "We screened 723 miRNAs by microarray and selected ......" | 23945108 | |
hsa-miR-125b-5p | bladder cancer | motility | "Hsa miR 125b suppresses bladder cancer development ......" | 24396870 | |
hsa-miR-125b-5p | bladder cancer | motility | "Hsa miR 125b suppresses bladder cancer development ......" | 24512851 | |
hsa-miR-125b-5p | bladder cancer | progression; poor survival | "Of the eight most important progression-related mi ......" | 25990459 | |
hsa-miR-125b-5p | bladder cancer | poor survival | "We identified an eight-miRNA signature including t ......" | 25991007 | |
hsa-miR-125b-5p | breast cancer | poor survival | "A short hairpin DNA analogous to miR 125b inhibits ......" | 19825990 | |
hsa-miR-125b-5p | breast cancer | drug resistance | "In this study we utilized a miRNA array to compare ......" | 20460378 | |
hsa-miR-125b-5p | breast cancer | motility | "Expression profiling of 365 miRNA by real-time qua ......" | 21375733 | |
hsa-miR-125b-5p | breast cancer | poor survival; tumorigenesis; worse prognosis | "miR 125b is methylated and functions as a tumor su ......" | 21444677 | |
hsa-miR-125b-5p | breast cancer | motility | "miR 125b targets ARID3B in breast cancer cells; Am ......" | 22307404 | Cell migration assay |
hsa-miR-125b-5p | breast cancer | drug resistance | "Circulating MiR 125b as a marker predicting chemor ......" | 22523546 | |
hsa-miR-125b-5p | breast cancer | metastasis | "miR-125b is down-regulated in human breast cancer ......" | 22693547 | Cell migration assay; Wound Healing Assay; Western blot; Luciferase |
hsa-miR-125b-5p | breast cancer | metastasis; drug resistance | "miR 125b regulates side population in breast cance ......" | 23606360 | |
hsa-miR-125b-5p | breast cancer | tumorigenesis | "miR 125b acts as a tumor suppressor in breast tumo ......" | 24098452 | |
hsa-miR-125b-5p | breast cancer | drug resistance | "We created a doxorubicin-resistant MCF-7 MCF-/Adr ......" | 25451164 | MTT assay |
hsa-miR-125b-5p | breast cancer | drug resistance | "MiR 125b regulates epithelial mesenchymal transiti ......" | 25605244 | |
hsa-miR-125b-5p | breast cancer | drug resistance; worse prognosis | "To gain further insight into the molecular mechani ......" | 25633049 | |
hsa-miR-125b-5p | breast cancer | drug resistance | "The role of miR 125b mitochondria caspase 3 pathwa ......" | 25894378 | Luciferase |
hsa-miR-125b-5p | breast cancer | malignant trasformation; metastasis; tumor size; progression | "Dysregulated miR-125 observed in multiple cancer t ......" | 26782438 | |
hsa-miR-125b-5p | breast cancer | worse prognosis; drug resistance | "miR 125b inhibited epithelial mesenchymal transiti ......" | 27226726 | |
hsa-miR-125b-5p | breast cancer | worse prognosis | "miR 125b 1 is repressed by histone modifications i ......" | 27386402 | |
hsa-miR-125b-5p | breast cancer | progression | "We identified eight microRNAs miR-10a miR-10b miR- ......" | 27433802 | |
hsa-miR-125b-5p | breast cancer | poor survival | "In this multicenter study a 10-miRNA classifier in ......" | 27566954 | |
hsa-miR-125b-5p | cervical and endocervical cancer | drug resistance | "OCT4 induces upregulation of miR-125b through dire ......" | 23928699 | Luciferase |
hsa-miR-125b-5p | cervical and endocervical cancer | immune resistance; tumorigenesis | "MicroRNAs as biomarkers of cervical cancer develop ......" | 24402874 | |
hsa-miR-125b-5p | colorectal cancer | progression | "Clinicopathological significance of microRNA 21 an ......" | 19921579 | |
hsa-miR-125b-5p | colorectal cancer | staging; tumor size; worse prognosis; poor survival; progression | "MicroRNA miR 125b is a prognostic marker in human ......" | 21399871 | |
hsa-miR-125b-5p | colorectal cancer | metastasis | "The expression of miR-106a was found to be upregul ......" | 24746948 | |
hsa-miR-125b-5p | colorectal cancer | worse prognosis | "Screening miRNAs for early diagnosis of colorectal ......" | 27022275 | |
hsa-miR-125b-5p | endometrial cancer | staging | "MiR 125b promotes proliferation and migration of t ......" | 21970405 | Western blot; Cell migration assay; Wound Healing Assay; Luciferase |
hsa-miR-125b-5p | endometrial cancer | tumorigenesis | "The objective of this study was to investigate the ......" | 22460089 | Transwell assay; Western blot; Luciferase; RNAi |
hsa-miR-125b-5p | esophageal cancer | tumorigenesis; progression | "HPV 16 E6 promotes cell growth of esophageal cance ......" | 26722596 | Colony formation |
hsa-miR-125b-5p | gastric cancer | progression | "353 gastric samples from two independent subsets o ......" | 20022810 | |
hsa-miR-125b-5p | gastric cancer | poor survival | "RNA and protein expression were analyzed by RT-PCR ......" | 24352645 | |
hsa-miR-125b-5p | gastric cancer | drug resistance | "Expression profiling and functional analysis of hs ......" | 24846940 | |
hsa-miR-125b-5p | gastric cancer | worse prognosis; cell migration; staging; metastasis; tumor size | "MiR 125b promotes cell migration and invasion by t ......" | 25240408 | Western blot; Transwell assay; Luciferase |
hsa-miR-125b-5p | gastric cancer | cell migration | "miR 101 2 miR 125b 2 and miR 451a act as potential ......" | 26458815 | Western blot; Colony formation |
hsa-miR-125b-5p | gastric cancer | staging; metastasis; drug resistance; progression | "miR 125b Suppresses Proliferation and Invasion by ......" | 26504803 | |
hsa-miR-125b-5p | gastric cancer | metastasis; staging; cell migration | "Here we investigate the role of miR-125b in gastri ......" | 27220320 | Luciferase |
hsa-miR-125b-5p | glioblastoma | drug resistance | "MicroRNAs miRNAs are small non-coding RNA molecule ......" | 21879257 | |
hsa-miR-125b-5p | glioblastoma | cell migration | "Myc associated zinc finger protein MAZ is regulate ......" | 22415301 | |
hsa-miR-125b-5p | glioblastoma | staging | "Functional differences of miR 125b on the invasion ......" | 22711523 | |
hsa-miR-125b-5p | glioblastoma | malignant trasformation | "In this study we aimed to identify the combined ef ......" | 23835866 | Transwell assay |
hsa-miR-125b-5p | glioblastoma | drug resistance | "miR 125b inhibitor may enhance the invasion preven ......" | 23857508 | |
hsa-miR-125b-5p | glioblastoma | malignant trasformation | "MiR 125b acts as an oncogene in glioblastoma cells ......" | 24169356 | Colony formation; Luciferase; Western blot |
hsa-miR-125b-5p | glioblastoma | progression | "miR 125b promotes cell proliferation by directly t ......" | 24356103 | |
hsa-miR-125b-5p | glioblastoma | drug resistance | "miR 125b inhibitor enhance the chemosensitivity of ......" | 24643683 | |
hsa-miR-125b-5p | glioblastoma | poor survival | "An inverse relationship between miR-125b and nesti ......" | 24817689 | |
hsa-miR-125b-5p | glioblastoma | drug resistance; poor survival | "miR 125b controls apoptosis and temozolomide resis ......" | 24901050 | |
hsa-miR-125b-5p | glioblastoma | staging | "Serum and tissues miRNAs expression in patients wi ......" | 27476114 | |
hsa-miR-125b-5p | head and neck cancer | malignant trasformation; progression | "Loss of miR 125b 1 contributes to head and neck ca ......" | 23416980 | |
hsa-miR-125b-5p | head and neck cancer | worse prognosis | "Conversely decreased expressions of miR-153 miR-20 ......" | 25677760 | |
hsa-miR-125b-5p | kidney renal cell cancer | poor survival; recurrence; staging | "Tumor miR 125b predicts recurrence and survival of ......" | 25155155 | |
hsa-miR-125b-5p | kidney renal cell cancer | staging | "This study aims to profile dysregulated microRNA m ......" | 25938468 | |
hsa-miR-125b-5p | kidney renal cell cancer | worse prognosis | "We found that elevated expression of miR-21 miR-12 ......" | 26416448 | |
hsa-miR-125b-5p | liver cancer | poor survival; worse prognosis | "Then the expressions of 8 differentially expressed ......" | 18649363 | |
hsa-miR-125b-5p | liver cancer | tumorigenesis; cell migration | "Our previous study showed that miR-125b was a prog ......" | 20827722 | |
hsa-miR-125b-5p | liver cancer | malignant trasformation; cell migration | "Our aim was to evaluate the role of aberrantly exp ......" | 21703189 | Luciferase |
hsa-miR-125b-5p | liver cancer | progression | "In this study we demonstrated the down-regulation ......" | 22942733 | |
hsa-miR-125b-5p | liver cancer | staging | "Profiles of serum microRNAs; miR 125b 5p and miR22 ......" | 24595450 | |
hsa-miR-125b-5p | liver cancer | recurrence; poor survival; worse prognosis; tumorigenesis | "This study investigates the involvement of miR-125 ......" | 24811246 | Luciferase |
hsa-miR-125b-5p | liver cancer | drug resistance; malignant trasformation | "The microRNA miR-125 family has been implicated in ......" | 24865963 | |
hsa-miR-125b-5p | liver cancer | differentiation; drug resistance; metastasis | "Among these miRNAs miR-125b expression was most st ......" | 25953743 | |
hsa-miR-125b-5p | liver cancer | recurrence; poor survival | "In the present study TaqMan Real-time PCR microRNA ......" | 26176380 | |
hsa-miR-125b-5p | liver cancer | tumor size | "Our previous study has hinted that serum microRNA- ......" | 27267832 | |
hsa-miR-125b-5p | liver cancer | metastasis | "MicroRNAs miR 125b and miR 100 suppress metastasis ......" | 27577856 | |
hsa-miR-125b-5p | lung cancer | progression | "We succeeded in establishing the MTA1 knockdown NS ......" | 22576802 | RNAi |
hsa-miR-125b-5p | lung cancer | staging; metastasis; progression | "In this work the methylation of six miRNA genes mi ......" | 24450160 | |
hsa-miR-125b-5p | lung cancer | drug resistance | "Up regulation of miR 125b reverses epithelial mese ......" | 26351908 | |
hsa-miR-125b-5p | lung cancer | progression; drug resistance | "Expression levels of miR-19b miR-126 miR-25 miR-20 ......" | 26986825 | |
hsa-miR-125b-5p | lung squamous cell cancer | worse prognosis; staging; poor survival | "Circulating miR 125b is a novel biomarker for scre ......" | 22806310 | |
hsa-miR-125b-5p | lung squamous cell cancer | metastasis; cell migration; progression | "MTA1 promotes the invasion and migration of non sm ......" | 23718732 | |
hsa-miR-125b-5p | lung squamous cell cancer | cell migration | "High expression of kinesin light chain 2 a novel t ......" | 25668010 | Luciferase |
hsa-miR-125b-5p | lung squamous cell cancer | metastasis; staging | "Here we evaluated the potential role of miR-125b i ......" | 26388699 | Western blot |
hsa-miR-125b-5p | lymphoma | drug resistance; poor survival | "Using cutaneous T-cell lymphoma CTCL as a model of ......" | 23527180 | |
hsa-miR-125b-5p | lymphoma | differentiation | "Aberrant expression of oncogenic miRNAs including ......" | 24479800 | |
hsa-miR-125b-5p | melanoma | malignant trasformation; metastasis; progression | "Downregulation of miR 125b in metastatic cutaneous ......" | 20827223 | |
hsa-miR-125b-5p | melanoma | metastasis; malignant trasformation | "MicroRNA miR 125b induces senescence in human mela ......" | 21460750 | |
hsa-miR-125b-5p | melanoma | progression; malignant trasformation | "MicroRNA miR 125b controls melanoma progression by ......" | 22797068 | Luciferase |
hsa-miR-125b-5p | melanoma | malignant trasformation | "Expression of the miRNA miR-125b and serine/threon ......" | 24635082 | Cell Proliferation Assay; Western blot; Luciferase |
hsa-miR-125b-5p | melanoma | malignant trasformation; metastasis; progression | "miR 125b induces cellular senescence in malignant ......" | 24762088 | Western blot; Flow cytometry |
hsa-miR-125b-5p | melanoma | staging | "To analyze miR-125b levels in serum and in exosome ......" | 24878024 | |
hsa-miR-125b-5p | melanoma | progression; poor survival; cell migration | "Here we used in silico analysis of microRNA expres ......" | 26968260 | |
hsa-miR-125b-5p | ovarian cancer | drug resistance | "High-throughput analysis of the miRNA profile in a ......" | 18823650 | |
hsa-miR-125b-5p | ovarian cancer | drug resistance | "miR 125b confers resistance of ovarian cancer cell ......" | 21823019 | Flow cytometry; Western blot; Luciferase |
hsa-miR-125b-5p | ovarian cancer | metastasis; recurrence; tumorigenesis | "PPARγ inhibits ovarian cancer cells proliferation ......" | 25944662 | |
hsa-miR-125b-5p | ovarian cancer | cell migration | "miRNA mimics and miRNA inhibitors were used in qua ......" | 26646586 | Western blot; Luciferase |
hsa-miR-125b-5p | ovarian cancer | staging; metastasis | "Utility of Serum miR 125b as a Diagnostic and Prog ......" | 27092777 | |
hsa-miR-125b-5p | ovarian cancer | drug resistance; metastasis; progression; cell migration | "MicroRNA-125b miR-125b is overexpressed in several ......" | 27383536 | Western blot; Luciferase |
hsa-miR-125b-5p | ovarian cancer | progression; poor survival | "Using customized TaqMan low density miRNA arrays w ......" | 27636713 | |
hsa-miR-125b-5p | pancreatic cancer | staging | "Based on relevance to cancer a seven-miRNA signatu ......" | 25184537 | |
hsa-miR-125b-5p | prostate cancer | malignant trasformation | "In this study we found differential expression of ......" | 18056640 | |
hsa-miR-125b-5p | prostate cancer | staging | "To overcome the lack of reproducibility we profile ......" | 21212412 | |
hsa-miR-125b-5p | prostate cancer | progression | "Aberrant expressions of some miRNAs like miR-221/2 ......" | 24386864 | |
hsa-miR-125b-5p | prostate cancer | staging; progression | "Microarray and Q-RT-PCR analyses identified 43 miR ......" | 24583788 | |
hsa-miR-125b-5p | prostate cancer | tumorigenesis; progression | "Dual Action of miR 125b As a Tumor Suppressor and ......" | 26544868 | Luciferase |
hsa-miR-125b-5p | retinoblastoma | metastasis | "Among them hsa-miR-373 hsa-miR-125b and hsa-miR-18 ......" | 26730174 | |
hsa-miR-125b-5p | retinoblastoma | staging | "The miRNA miR-125b is dysregulated in various huma ......" | 27518550 | Luciferase |
hsa-miR-125b-5p | sarcoma | progression | "miR 125b suppresses the proliferation and migratio ......" | 22093834 | |
hsa-miR-125b-5p | sarcoma | drug resistance | "miR 125b develops chemoresistance in Ewing sarcoma ......" | 23497288 | |
hsa-miR-125b-5p | sarcoma | progression; tumorigenesis | "MiR 125b inhibits cell biological progression of E ......" | 24517182 | Western blot |
hsa-miR-125b-5p | sarcoma | metastasis; progression; worse prognosis; staging; poor survival | "Upregulation of miR 300 and downregulation of miR ......" | 26330295 | |
hsa-miR-125b-5p | sarcoma | progression; drug resistance | "Circulating miR 125b as a biomarker of Ewing's sar ......" | 26782555 | |
hsa-miR-125b-5p | thyroid cancer | malignant trasformation | "A miRNA array was used to identify differentially ......" | 22006248 |
Reported gene related to hsa-miR-125b-5p
miRNA | cancer | gene | reporting | PUBMED |
---|---|---|---|---|
hsa-miR-125b-5p | breast cancer | TP53 | "The carboxy terminal domain of connexin 43 CT Cx4 ......" | 26335100 |
hsa-miR-125b-5p | cervical and endocervical cancer | TP53 | "miR-34a is directly regulated by p53 and acts as t ......" | 24402874 |
hsa-miR-125b-5p | colorectal cancer | TP53 | "In vitro assays revealed that overexpression of mi ......" | 21399871 |
hsa-miR-125b-5p | gastric cancer | TP53 | "The results revealed that hsa-miR-125b may regulat ......" | 24846940 |
hsa-miR-125b-5p | glioblastoma | TP53 | "MiR 125b acts as an oncogene in glioblastoma cells ......" | 24169356 |
hsa-miR-125b-5p | liver cancer | TP53 | "Furthermore treatment of HCC cells with 5-aza-2'-d ......" | 23079745 |
hsa-miR-125b-5p | lung cancer | TP53 | "In this study we have investigated the delivery an ......" | 26686386 |
hsa-miR-125b-5p | melanoma | TP53 | "A stable overexpression of miR-125b in human melan ......" | 24762088 |
hsa-miR-125b-5p | pancreatic cancer | TP53 | "TP53 and hsa-miR-125b were observed to form a self ......" | 24137477 |
hsa-miR-125b-5p | prostate cancer | TP53 | "In this study we further extend our studies by sho ......" | 23585871 |
hsa-miR-125b-5p | breast cancer | BAK1 | "We subsequently evaluated the effect of miR-125b-1 ......" | 27386402 |
hsa-miR-125b-5p | breast cancer | BAK1 | "Moreover we demonstrated that the pro-apoptotic Bc ......" | 20460378 |
hsa-miR-125b-5p | cervical and endocervical cancer | BAK1 | "In contrast miR-125b sponge impaired the anti-apop ......" | 23928699 |
hsa-miR-125b-5p | glioblastoma | BAK1 | "miR 125b inhibitor enhance the chemosensitivity of ......" | 24643683 |
hsa-miR-125b-5p | ovarian cancer | BAK1 | "An in vitro cytotoxicity assay and apoptosis assay ......" | 21823019 |
hsa-miR-125b-5p | prostate cancer | BAK1 | "In addition transfection of synthetic miR-125b sti ......" | 18056640 |
hsa-miR-125b-5p | breast cancer | ERBB2 | "The noncoding RNA miR-125b has been described to r ......" | 19825990 |
hsa-miR-125b-5p | breast cancer | ERBB2 | "Due to the heterogeneity of breast cancers MCF7 ce ......" | 22307404 |
hsa-miR-125b-5p | endometrial cancer | ERBB2 | "RNA interference technology was used to confirm th ......" | 22460089 |
hsa-miR-125b-5p | prostate cancer | ERBB2 | "Relevant luciferase+3'-UTR expression studies conf ......" | 26544868 |
hsa-miR-125b-5p | sarcoma | ERBB2 | "miR 125b acts as a tumor suppressor in chondrosarc ......" | 26966351 |
hsa-miR-125b-5p | breast cancer | BCL2 | "Moreover we demonstrated that the pro-apoptotic Bc ......" | 20460378 |
hsa-miR-125b-5p | glioblastoma | BCL2 | "Moreover we demonstrated that the pro-apoptotic Bc ......" | 24643683 |
hsa-miR-125b-5p | ovarian cancer | BCL2 | "miR 125b confers resistance of ovarian cancer cell ......" | 21823019 |
hsa-miR-125b-5p | sarcoma | BCL2 | "Our data also verified that Bcl-2 is the target of ......" | 26744308 |
hsa-miR-125b-5p | liver cancer | AFP | "Combination of miR 125b and miR 27a enhances sensi ......" | 26637228 |
hsa-miR-125b-5p | liver cancer | AFP | "Multivariate analysis revealed that miR-125b tumor ......" | 27267832 |
hsa-miR-125b-5p | liver cancer | AFP | "miR-125b expression was also negatively correlated ......" | 24811246 |
hsa-miR-125b-5p | breast cancer | MCL1 | "However the overexpression of miR-125b did not inf ......" | 25894378 |
hsa-miR-125b-5p | gastric cancer | MCL1 | "miR 125b Suppresses Proliferation and Invasion by ......" | 26504803 |
hsa-miR-125b-5p | liver cancer | MCL1 | "The ectopic expression of miR-125b reduced the cel ......" | 22942733 |
hsa-miR-125b-5p | bladder cancer | SIRT7 | "Hsa miR 125b suppresses bladder cancer development ......" | 24512851 |
hsa-miR-125b-5p | bladder cancer | SIRT7 | "Hsa miR 125b suppresses bladder cancer development ......" | 24396870 |
hsa-miR-125b-5p | liver cancer | SIRT7 | "Four out of nine patients with induced SIRT7 carri ......" | 23079745 |
hsa-miR-125b-5p | ovarian cancer | BCL3 | "MiR 125b targets BCL3 and suppresses ovarian cance ......" | 20658525 |
hsa-miR-125b-5p | ovarian cancer | BCL3 | "In ovarian cancer miR-125b has been shown to be do ......" | 25944662 |
hsa-miR-125b-5p | breast cancer | BMPR1B | "A risk variant in an miR 125b binding site in BMPR ......" | 19738052 |
hsa-miR-125b-5p | prostate cancer | BMPR1B | "Our findings show that rs1434536 in the 3'UTR of B ......" | 21556765 |
hsa-miR-125b-5p | bladder cancer | E2F3 | "E2F3 which was critical for G1/S transition and wa ......" | 20549700 |
hsa-miR-125b-5p | breast cancer | E2F3 | "Moreover we demonstrated that the E2F3 was a direc ......" | 22523546 |
hsa-miR-125b-5p | ovarian cancer | EIF4EBP1 | "Increased expression of miR-125a and miR-125b inhi ......" | 26646586 |
hsa-miR-125b-5p | prostate cancer | EIF4EBP1 | "Using a bioinformatics approach we have identified ......" | 17891175 |
hsa-miR-125b-5p | breast cancer | ESR1 | "In this study we examined the global structural ch ......" | 20978686 |
hsa-miR-125b-5p | breast cancer | ESR1 | "Overexpression of the putative tumor suppressor mi ......" | 21375733 |
hsa-miR-125b-5p | colorectal cancer | IBSP | "We investigated the methylation status of miR-125 ......" | 26693202 |
hsa-miR-125b-5p | sarcoma | IBSP | "Bisulfite sequencing analysis BSP was used to dete ......" | 27576314 |
hsa-miR-125b-5p | bladder cancer | MALAT1 | "Hsa miR 125b suppresses bladder cancer development ......" | 24512851 |
hsa-miR-125b-5p | bladder cancer | MALAT1 | "Hsa miR 125b suppresses bladder cancer development ......" | 24396870 |
hsa-miR-125b-5p | bladder cancer | MMP13 | "We also provided the first evidence that miR-125b ......" | 23425975 |
hsa-miR-125b-5p | lung squamous cell cancer | MMP13 | "This study aimed to determine the relationship bet ......" | 25772251 |
hsa-miR-125b-5p | gastric cancer | NEU1 | "STARD13 and NEU1 were identified as direct target ......" | 27220320 |
hsa-miR-125b-5p | pancreatic cancer | NEU1 | "Thus far two of these target genes BBC3 and NEU1 t ......" | 25184537 |
hsa-miR-125b-5p | glioblastoma | NOTCH1 | "Further research on the mechanism demonstrated tha ......" | 23835866 |
hsa-miR-125b-5p | liver cancer | NOTCH1 | "Addition of GLPS to treat T cells inhibited Notch1 ......" | 25889022 |
hsa-miR-125b-5p | endometrial cancer | NUPR1 | "In addition in vivo tumor formation assay confirme ......" | 21970405 |
hsa-miR-125b-5p | lung squamous cell cancer | NUPR1 | "Further tumor protein 53-induced nuclear protein 1 ......" | 26388699 |
hsa-miR-125b-5p | bladder cancer | PCNA | "In addition we observed that transfection of miR-1 ......" | 20549700 |
hsa-miR-125b-5p | melanoma | PCNA | "Mel-Juso cells overexpressing miR-125b were tumour ......" | 24762088 |
hsa-miR-125b-5p | cervical and endocervical cancer | PIK3CD | "we identified phosphoinositide 3-kinase catalytic ......" | 23160634 |
hsa-miR-125b-5p | sarcoma | PIK3CD | "Further quantitative RT-PCR and western blot assay ......" | 24517182 |
hsa-miR-125b-5p | glioblastoma | PROM1 | "Functional differences of miR 125b on the invasion ......" | 22711523 |
hsa-miR-125b-5p | glioblastoma | PROM1 | "miR-125b as one of neuronal miRNAs is the most sig ......" | 22999819 |
hsa-miR-125b-5p | breast cancer | SEMA4C | "MiR 125b regulates epithelial mesenchymal transiti ......" | 25605244 |
hsa-miR-125b-5p | lung cancer | SEMA4C | "Moreover we found that miR-125b governed PR-induce ......" | 26351908 |
hsa-miR-125b-5p | breast cancer | STARD13 | "In addition it was implied STARD13 DLC2 was a dire ......" | 22693547 |
hsa-miR-125b-5p | gastric cancer | STARD13 | "STARD13 and NEU1 were identified as direct target ......" | 27220320 |
hsa-miR-125b-5p | sarcoma | STAT3 | "Dual-luciferase reporter assay was used to identif ......" | 27576314 |
hsa-miR-125b-5p | sarcoma | STAT3 | "miR 125b suppresses the proliferation and migratio ......" | 22093834 |
hsa-miR-125b-5p | endometrial cancer | TP53INP1 | "MiR 125b promotes proliferation and migration of t ......" | 21970405 |
hsa-miR-125b-5p | lung squamous cell cancer | TP53INP1 | "Expressions of miR-125b and TP53INP1 were detected ......" | 26388699 |
hsa-miR-125b-5p | breast cancer | ABCB1 | "The role of miR 125b mitochondria caspase 3 pathwa ......" | 25894378 |
hsa-miR-125b-5p | prostate cancer | AGO2 | "Downregulation of AGO2 enhanced expression of miR- ......" | 24805183 |
hsa-miR-125b-5p | liver cancer | ANGPT2 | "Taken together our findings imply that miR-125b an ......" | 27577856 |
hsa-miR-125b-5p | breast cancer | ARID3B | "miR 125b targets ARID3B in breast cancer cells; Am ......" | 22307404 |
hsa-miR-125b-5p | prostate cancer | ATP8A2 | "A miR 125b binding site polymorphism in bone morph ......" | 21556765 |
hsa-miR-125b-5p | pancreatic cancer | BBC3 | "Thus far two of these target genes BBC3 and NEU1 t ......" | 25184537 |
hsa-miR-125b-5p | breast cancer | CASP3 | "The role of miR 125b mitochondria caspase 3 pathwa ......" | 25894378 |
hsa-miR-125b-5p | bladder cancer | CCNA2 | "In addition we observed that transfection of miR-1 ......" | 20549700 |
hsa-miR-125b-5p | melanoma | CCND1 | "Mel-Juso cells overexpressing miR-125b were tumour ......" | 24762088 |
hsa-miR-125b-5p | prostate cancer | CDKN2A | "In this study we further extend our studies by sho ......" | 23585871 |
hsa-miR-125b-5p | cervical and endocervical cancer | DLL1 | "MiR 125b inhibits tumor growth and promotes apopto ......" | 23160634 |
hsa-miR-125b-5p | breast cancer | DYNLL2 | "In addition it was implied STARD13 DLC2 was a dire ......" | 22693547 |
hsa-miR-125b-5p | glioblastoma | E2F2 | "miR 125b regulates the proliferation of glioblasto ......" | 22999819 |
hsa-miR-125b-5p | lung cancer | EGFR | "In a word Circulating 5 selected miRNAs may especi ......" | 26175938 |
hsa-miR-125b-5p | liver cancer | EIF5A2 | "Among the 110 bioinformatically predicated candida ......" | 24811246 |
hsa-miR-125b-5p | breast cancer | ENPEP | "The expression of ENPEP and CK2-α was inversely c ......" | 24098452 |
hsa-miR-125b-5p | breast cancer | ETS1 | "miR 125b is methylated and functions as a tumor su ......" | 21444677 |
hsa-miR-125b-5p | sarcoma | EWSR1 | "We found miR-125b to be upregulated in two differe ......" | 23497288 |
hsa-miR-125b-5p | liver cancer | FOXP3 | "Addition of GLPS to treat T cells inhibited Notch1 ......" | 25889022 |
hsa-miR-125b-5p | breast cancer | GJA1 | "The carboxy terminal domain of connexin 43 CT Cx4 ......" | 26335100 |
hsa-miR-125b-5p | melanoma | GLB1 | "A stable overexpression of miR-125b in human melan ......" | 24762088 |
hsa-miR-125b-5p | glioblastoma | GLI1 | "Thirteen miRNAs including miR-125b-1 were downregu ......" | 24688313 |
hsa-miR-125b-5p | liver cancer | HOTTIP | "Long non coding RNA HOTTIP is frequently up regula ......" | 25424744 |
hsa-miR-125b-5p | liver cancer | IL6R | "The ectopic expression of miR-125b reduced the cel ......" | 22942733 |
hsa-miR-125b-5p | B cell lymphoma | IRF4 | "We provide experimental evidence that these change ......" | 19047678 |
hsa-miR-125b-5p | melanoma | JUN | "MicroRNA miR 125b controls melanoma progression by ......" | 22797068 |
hsa-miR-125b-5p | lung squamous cell cancer | KLC2 | "This study is to identify the function of KLC2 and ......" | 25668010 |
hsa-miR-125b-5p | glioblastoma | LIN28A | "miR 125b promotes cell proliferation by directly t ......" | 24356103 |
hsa-miR-125b-5p | liver cancer | LIN28B | "Silencing of LIN28B recapitulated the effects of m ......" | 20827722 |
hsa-miR-125b-5p | B cell lymphoma | LMO2 | "We provide experimental evidence that these change ......" | 19047678 |
hsa-miR-125b-5p | head and neck cancer | MAP2K6 | "We report that miR-125b-1 causes mitogen-activated ......" | 23416980 |
hsa-miR-125b-5p | breast cancer | MAP2K7 | "miR 125b inhibited epithelial mesenchymal transiti ......" | 27226726 |
hsa-miR-125b-5p | melanoma | MAP3K11 | "Expression of the miRNA miR-125b and serine/threon ......" | 24635082 |
hsa-miR-125b-5p | melanoma | MARK2 | "Expression of the miRNA miR-125b and serine/threon ......" | 24635082 |
hsa-miR-125b-5p | glioblastoma | MAZ | "Here we report that miR-125b is down-regulated in ......" | 22415301 |
hsa-miR-125b-5p | prostate cancer | MBD2 | "The histone demethylase PHF8 promotes prostate can ......" | 26309412 |
hsa-miR-125b-5p | prostate cancer | MDM2 | "Conversely treatment of prostate cancer cells with ......" | 23585871 |
hsa-miR-125b-5p | breast cancer | MEMO1 | "Overexpression of the putative tumor suppressor mi ......" | 21375733 |
hsa-miR-125b-5p | liver cancer | MMP2 | "Furthermore modulation of miR-125b also distorted ......" | 21703189 |
hsa-miR-125b-5p | lung squamous cell cancer | MTA1 | "MTA1 promotes the invasion and migration of non sm ......" | 23718732 |
hsa-miR-125b-5p | lymphoma | MXD4 | "Bortezomib repressed cMyc and simultaneously induc ......" | 23527180 |
hsa-miR-125b-5p | lung squamous cell cancer | MYL4 | "High expression of kinesin light chain 2 a novel t ......" | 25668010 |
hsa-miR-125b-5p | melanoma | NEDD9 | "Furthermore we show that neural precursor cell exp ......" | 26968260 |
hsa-miR-125b-5p | glioblastoma | NES | "An inverse relationship between miR-125b and nesti ......" | 24817689 |
hsa-miR-125b-5p | glioblastoma | NKIRAS2 | "miR 125b controls apoptosis and temozolomide resis ......" | 24901050 |
hsa-miR-125b-5p | lung cancer | NPS | "Systemic plasmid DNA delivery with dual CD44/EGFR- ......" | 26686386 |
hsa-miR-125b-5p | breast cancer | NR4A1 | "There were no significant correlations between miR ......" | 26782438 |
hsa-miR-125b-5p | liver cancer | PGF | "Placenta growth factor was identified as a target ......" | 21703189 |
hsa-miR-125b-5p | prostate cancer | PHF8 | "The histone demethylase PHF8 promotes prostate can ......" | 26309412 |
hsa-miR-125b-5p | glioblastoma | PIAS3 | "miR 125b inhibitor may enhance the invasion preven ......" | 23857508 |
hsa-miR-125b-5p | liver cancer | PIGF | "Overexpression of miR-125b in HCC cells decreased ......" | 21703189 |
hsa-miR-125b-5p | prostate cancer | PPFIA3 | "A miR 125b binding site polymorphism in bone morph ......" | 21556765 |
hsa-miR-125b-5p | gastric cancer | PPP1CA | "MiR 125b promotes cell migration and invasion by t ......" | 25240408 |
hsa-miR-125b-5p | melanoma | PRDX2 | "Treatment with 5-Aza but not with TSA reduced the ......" | 22213330 |
hsa-miR-125b-5p | prostate cancer | PTEN | "Relevant luciferase+3'-UTR expression studies conf ......" | 26544868 |
hsa-miR-125b-5p | breast cancer | RAF1 | "A short hairpin DNA analogous to miR 125b inhibits ......" | 19825990 |
hsa-miR-125b-5p | lung squamous cell cancer | SCLC1 | "Cisplatin CDDP treatment of SCLC cells resulted in ......" | 25833836 |
hsa-miR-125b-5p | liver cancer | SMAD2 | "Mechanistically our data revealed that miR-125b su ......" | 25953743 |
hsa-miR-125b-5p | bladder cancer | SPHK1 | "Overexpression of miR-125b inhibited cellular grow ......" | 26807182 |
hsa-miR-125b-5p | liver cancer | SUV39H1 | "We also identified microRNA-125b miR-125b as a pos ......" | 22991213 |
hsa-miR-125b-5p | head and neck cancer | TACSTD2 | "Loss of miR 125b 1 contributes to head and neck ca ......" | 23416980 |
hsa-miR-125b-5p | melanoma | TCF4 | "Also transcription factor 4 associated with epithe ......" | 26968260 |
hsa-miR-125b-5p | glioblastoma | TNFAIP3 | "miR 125b controls apoptosis and temozolomide resis ......" | 24901050 |
hsa-miR-125b-5p | lymphoma | TSPYL2 | "Using cutaneous T-cell lymphoma CTCL as a model of ......" | 23527180 |
hsa-miR-125b-5p | breast cancer | TSTA3 | "miR-125a-5p and miR-125b are upstream targets of T ......" | 26531722 |
hsa-miR-125b-5p | melanoma | VDR | "The expression of VDR mRNA protein and two candida ......" | 22213330 |
hsa-miR-125b-5p | glioblastoma | VEGFA | "Here we report that miR-125b is down-regulated in ......" | 22415301 |
Expression profile in cancer corhorts:
Putative target regulations
miRNA | Gene | Cancer | Interaction | Correlation beta |
---|---|---|---|---|
hsa-miR-125b-5p | ACLY | 15 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; LUSC; THCA; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.064; TCGA BRCA -0.139; TCGA CESC -0.134; TCGA COAD -0.053; TCGA ESCA -0.154; TCGA HNSC -0.234; TCGA KIRC -0.467; TCGA KIRP -0.146; TCGA LGG -0.1; TCGA LIHC -0.274; TCGA LUAD -0.086; TCGA LUSC -0.184; TCGA THCA -0.177; TCGA STAD -0.083; TCGA UCEC -0.064 |
hsa-miR-125b-5p | ADRM1 | 9 cancers: BLCA; BRCA; ESCA; HNSC; LIHC; LUSC; OV; PAAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.052; TCGA BRCA -0.271; TCGA ESCA -0.118; TCGA HNSC -0.104; TCGA LIHC -0.062; TCGA LUSC -0.148; TCGA OV -0.158; TCGA PAAD -0.317; TCGA UCEC -0.116 |
hsa-miR-125b-5p | AKT1 | 10 cancers: BLCA; BRCA; CESC; COAD; HNSC; LGG; LUSC; OV; PAAD; SARC | miRNAWalker2 validate; miRTarBase | TCGA BLCA -0.075; TCGA BRCA -0.198; TCGA CESC -0.054; TCGA COAD -0.056; TCGA HNSC -0.076; TCGA LGG -0.071; TCGA LUSC -0.1; TCGA OV -0.077; TCGA PAAD -0.115; TCGA SARC -0.093 |
hsa-miR-125b-5p | ARID3B | 14 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRC; KIRP; LIHC; LUSC; PRAD; SARC; THCA; UCEC | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | TCGA BLCA -0.135; TCGA BRCA -0.115; TCGA CESC -0.11; TCGA COAD -0.06; TCGA ESCA -0.26; TCGA HNSC -0.103; TCGA KIRC -0.157; TCGA KIRP -0.093; TCGA LIHC -0.19; TCGA LUSC -0.135; TCGA PRAD -0.076; TCGA SARC -0.132; TCGA THCA -0.088; TCGA UCEC -0.068 |
hsa-miR-125b-5p | ATP5B | 13 cancers: BLCA; BRCA; COAD; ESCA; LGG; LUAD; LUSC; OV; PAAD; PRAD; THCA; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.069; TCGA BRCA -0.099; TCGA COAD -0.173; TCGA ESCA -0.16; TCGA LGG -0.097; TCGA LUAD -0.104; TCGA LUSC -0.168; TCGA OV -0.08; TCGA PAAD -0.144; TCGA PRAD -0.108; TCGA THCA -0.347; TCGA STAD -0.194; TCGA UCEC -0.066 |
hsa-miR-125b-5p | BAK1 | 16 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LGG; LIHC; LUAD; LUSC; OV; PAAD; PRAD; THCA; STAD; UCEC | miRNAWalker2 validate; miRTarBase; miRNATAP | TCGA BLCA -0.102; TCGA BRCA -0.174; TCGA CESC -0.145; TCGA COAD -0.198; TCGA ESCA -0.263; TCGA HNSC -0.336; TCGA LGG -0.095; TCGA LIHC -0.401; TCGA LUAD -0.06; TCGA LUSC -0.188; TCGA OV -0.198; TCGA PAAD -0.169; TCGA PRAD -0.108; TCGA THCA -0.201; TCGA STAD -0.119; TCGA UCEC -0.203 |
hsa-miR-125b-5p | CBFB | 10 cancers: BLCA; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; PRAD; STAD; UCEC | miRNAWalker2 validate; miRTarBase; miRNATAP | TCGA BLCA -0.058; TCGA HNSC -0.084; TCGA KIRC -0.145; TCGA KIRP -0.139; TCGA LGG -0.117; TCGA LIHC -0.115; TCGA LUAD -0.073; TCGA PRAD -0.155; TCGA STAD -0.154; TCGA UCEC -0.063 |
hsa-miR-125b-5p | CEBPG | 16 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRC; KIRP; LIHC; LUAD; LUSC; OV; SARC; THCA; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.077; TCGA BRCA -0.065; TCGA CESC -0.062; TCGA COAD -0.085; TCGA ESCA -0.23; TCGA HNSC -0.092; TCGA KIRC -0.085; TCGA KIRP -0.059; TCGA LIHC -0.072; TCGA LUAD -0.138; TCGA LUSC -0.261; TCGA OV -0.078; TCGA SARC -0.156; TCGA THCA -0.336; TCGA STAD -0.148; TCGA UCEC -0.068 |
hsa-miR-125b-5p | COX7C | 9 cancers: BLCA; BRCA; COAD; ESCA; LGG; LIHC; LUAD; LUSC; PAAD | miRNAWalker2 validate | TCGA BLCA -0.108; TCGA BRCA -0.121; TCGA COAD -0.073; TCGA ESCA -0.112; TCGA LGG -0.059; TCGA LIHC -0.066; TCGA LUAD -0.071; TCGA LUSC -0.141; TCGA PAAD -0.186 |
hsa-miR-125b-5p | DGAT1 | 11 cancers: BLCA; BRCA; CESC; COAD; ESCA; LGG; LIHC; OV; PAAD; STAD; UCEC | miRNAWalker2 validate; miRTarBase | TCGA BLCA -0.128; TCGA BRCA -0.131; TCGA CESC -0.106; TCGA COAD -0.162; TCGA ESCA -0.386; TCGA LGG -0.184; TCGA LIHC -0.084; TCGA OV -0.186; TCGA PAAD -0.377; TCGA STAD -0.161; TCGA UCEC -0.107 |
hsa-miR-125b-5p | E2F3 | 13 cancers: BLCA; BRCA; CESC; COAD; ESCA; KIRP; LGG; LIHC; LUAD; LUSC; PRAD; STAD; UCEC | miRNAWalker2 validate; miRTarBase; miRNATAP | TCGA BLCA -0.143; TCGA BRCA -0.091; TCGA CESC -0.119; TCGA COAD -0.054; TCGA ESCA -0.087; TCGA KIRP -0.103; TCGA LGG -0.095; TCGA LIHC -0.3; TCGA LUAD -0.119; TCGA LUSC -0.202; TCGA PRAD -0.239; TCGA STAD -0.147; TCGA UCEC -0.07 |
hsa-miR-125b-5p | E2F7 | 13 cancers: BLCA; BRCA; COAD; HNSC; KIRC; KIRP; LGG; LIHC; LUSC; PRAD; SARC; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.179; TCGA BRCA -0.515; TCGA COAD -0.207; TCGA HNSC -0.174; TCGA KIRC -0.672; TCGA KIRP -0.525; TCGA LGG -0.332; TCGA LIHC -0.644; TCGA LUSC -0.466; TCGA PRAD -0.248; TCGA SARC -0.405; TCGA STAD -0.465; TCGA UCEC -0.116 |
hsa-miR-125b-5p | EIF5 | 10 cancers: BLCA; CESC; COAD; ESCA; HNSC; LUSC; OV; PRAD; THCA; STAD | miRNAWalker2 validate | TCGA BLCA -0.101; TCGA CESC -0.064; TCGA COAD -0.116; TCGA ESCA -0.094; TCGA HNSC -0.122; TCGA LUSC -0.143; TCGA OV -0.074; TCGA PRAD -0.142; TCGA THCA -0.09; TCGA STAD -0.11 |
hsa-miR-125b-5p | ERBB3 | 9 cancers: BLCA; BRCA; CESC; ESCA; KIRC; LIHC; LUAD; STAD; UCEC | miRNAWalker2 validate; miRTarBase | TCGA BLCA -0.376; TCGA BRCA -0.246; TCGA CESC -0.139; TCGA ESCA -0.543; TCGA KIRC -0.397; TCGA LIHC -0.261; TCGA LUAD -0.277; TCGA STAD -0.253; TCGA UCEC -0.285 |
hsa-miR-125b-5p | ESRP2 | 11 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LUAD; LUSC; PAAD; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.199; TCGA BRCA -0.227; TCGA CESC -0.098; TCGA COAD -0.097; TCGA ESCA -0.168; TCGA HNSC -0.157; TCGA LUAD -0.128; TCGA LUSC -0.223; TCGA PAAD -0.168; TCGA STAD -0.27; TCGA UCEC -0.114 |
hsa-miR-125b-5p | FAM199X | 15 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LIHC; LUAD; LUSC; OV; PRAD; SARC; THCA; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.133; TCGA BRCA -0.084; TCGA CESC -0.062; TCGA COAD -0.083; TCGA ESCA -0.133; TCGA HNSC -0.177; TCGA LIHC -0.127; TCGA LUAD -0.14; TCGA LUSC -0.178; TCGA OV -0.124; TCGA PRAD -0.217; TCGA SARC -0.131; TCGA THCA -0.229; TCGA STAD -0.176; TCGA UCEC -0.138 |
hsa-miR-125b-5p | FAM60A | 9 cancers: BLCA; COAD; KIRP; LGG; LIHC; LUAD; LUSC; PRAD; STAD | miRNAWalker2 validate | TCGA BLCA -0.169; TCGA COAD -0.082; TCGA KIRP -0.087; TCGA LGG -0.171; TCGA LIHC -0.327; TCGA LUAD -0.226; TCGA LUSC -0.15; TCGA PRAD -0.191; TCGA STAD -0.21 |
hsa-miR-125b-5p | FAM91A1 | 14 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LIHC; LUAD; LUSC; OV; PRAD; THCA; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.051; TCGA BRCA -0.107; TCGA CESC -0.079; TCGA COAD -0.084; TCGA ESCA -0.236; TCGA HNSC -0.207; TCGA LIHC -0.076; TCGA LUAD -0.169; TCGA LUSC -0.124; TCGA OV -0.165; TCGA PRAD -0.167; TCGA THCA -0.05; TCGA STAD -0.241; TCGA UCEC -0.055 |
hsa-miR-125b-5p | FBXL20 | 9 cancers: BLCA; BRCA; CESC; HNSC; KIRC; LUAD; LUSC; OV; PRAD | miRNAWalker2 validate | TCGA BLCA -0.107; TCGA BRCA -0.06; TCGA CESC -0.069; TCGA HNSC -0.11; TCGA KIRC -0.066; TCGA LUAD -0.17; TCGA LUSC -0.188; TCGA OV -0.08; TCGA PRAD -0.143 |
hsa-miR-125b-5p | FRAT2 | 11 cancers: BLCA; BRCA; ESCA; KIRP; LGG; LIHC; LUAD; LUSC; PAAD; STAD; UCEC | miRNAWalker2 validate; miRNATAP | TCGA BLCA -0.14; TCGA BRCA -0.211; TCGA ESCA -0.245; TCGA KIRP -0.088; TCGA LGG -0.094; TCGA LIHC -0.192; TCGA LUAD -0.094; TCGA LUSC -0.264; TCGA PAAD -0.212; TCGA STAD -0.19; TCGA UCEC -0.121 |
hsa-miR-125b-5p | HK2 | 12 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRC; KIRP; LIHC; LUSC; STAD; UCEC | miRNAWalker2 validate; miRTarBase | TCGA BLCA -0.221; TCGA BRCA -0.162; TCGA CESC -0.257; TCGA COAD -0.25; TCGA ESCA -0.241; TCGA HNSC -0.38; TCGA KIRC -1.044; TCGA KIRP -0.503; TCGA LIHC -0.451; TCGA LUSC -0.288; TCGA STAD -0.438; TCGA UCEC -0.131 |
hsa-miR-125b-5p | HSPD1 | 14 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LIHC; LUAD; LUSC; PAAD; PRAD; THCA; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.073; TCGA BRCA -0.173; TCGA CESC -0.183; TCGA COAD -0.125; TCGA ESCA -0.223; TCGA HNSC -0.145; TCGA LIHC -0.198; TCGA LUAD -0.218; TCGA LUSC -0.321; TCGA PAAD -0.191; TCGA PRAD -0.171; TCGA THCA -0.111; TCGA STAD -0.312; TCGA UCEC -0.137 |
hsa-miR-125b-5p | KIF24 | 11 cancers: BLCA; BRCA; COAD; ESCA; KIRP; LIHC; LUSC; PAAD; SARC; THCA; STAD | miRNAWalker2 validate | TCGA BLCA -0.082; TCGA BRCA -0.283; TCGA COAD -0.124; TCGA ESCA -0.195; TCGA KIRP -0.102; TCGA LIHC -0.359; TCGA LUSC -0.213; TCGA PAAD -0.23; TCGA SARC -0.184; TCGA THCA -0.064; TCGA STAD -0.252 |
hsa-miR-125b-5p | LTV1 | 11 cancers: BLCA; COAD; ESCA; KIRP; LIHC; LUAD; LUSC; PRAD; THCA; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.06; TCGA COAD -0.075; TCGA ESCA -0.129; TCGA KIRP -0.059; TCGA LIHC -0.109; TCGA LUAD -0.074; TCGA LUSC -0.137; TCGA PRAD -0.179; TCGA THCA -0.061; TCGA STAD -0.143; TCGA UCEC -0.055 |
hsa-miR-125b-5p | MED1 | 9 cancers: BLCA; ESCA; HNSC; LIHC; LUAD; LUSC; PRAD; THCA; STAD | miRNAWalker2 validate | TCGA BLCA -0.075; TCGA ESCA -0.108; TCGA HNSC -0.062; TCGA LIHC -0.05; TCGA LUAD -0.086; TCGA LUSC -0.125; TCGA PRAD -0.097; TCGA THCA -0.141; TCGA STAD -0.086 |
hsa-miR-125b-5p | MTMR4 | 11 cancers: BLCA; BRCA; COAD; ESCA; LUAD; LUSC; PAAD; PRAD; SARC; THCA; STAD | miRNAWalker2 validate | TCGA BLCA -0.146; TCGA BRCA -0.108; TCGA COAD -0.104; TCGA ESCA -0.075; TCGA LUAD -0.126; TCGA LUSC -0.092; TCGA PAAD -0.103; TCGA PRAD -0.073; TCGA SARC -0.071; TCGA THCA -0.271; TCGA STAD -0.141 |
hsa-miR-125b-5p | MYO19 | 16 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LGG; LIHC; LUAD; LUSC; PAAD; PRAD; SARC; THCA; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.12; TCGA BRCA -0.267; TCGA CESC -0.084; TCGA COAD -0.164; TCGA ESCA -0.173; TCGA HNSC -0.116; TCGA LGG -0.157; TCGA LIHC -0.335; TCGA LUAD -0.185; TCGA LUSC -0.384; TCGA PAAD -0.269; TCGA PRAD -0.14; TCGA SARC -0.221; TCGA THCA -0.151; TCGA STAD -0.268; TCGA UCEC -0.126 |
hsa-miR-125b-5p | NDOR1 | 13 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LGG; LIHC; LUSC; OV; PAAD; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.069; TCGA BRCA -0.291; TCGA CESC -0.078; TCGA COAD -0.077; TCGA ESCA -0.217; TCGA HNSC -0.075; TCGA LGG -0.091; TCGA LIHC -0.269; TCGA LUSC -0.235; TCGA OV -0.067; TCGA PAAD -0.354; TCGA STAD -0.201; TCGA UCEC -0.086 |
hsa-miR-125b-5p | NKIRAS2 | 10 cancers: BLCA; BRCA; HNSC; KIRC; LGG; LIHC; LUAD; LUSC; PAAD; THCA | miRNAWalker2 validate; miRTarBase | TCGA BLCA -0.059; TCGA BRCA -0.097; TCGA HNSC -0.071; TCGA KIRC -0.103; TCGA LGG -0.182; TCGA LIHC -0.113; TCGA LUAD -0.086; TCGA LUSC -0.18; TCGA PAAD -0.089; TCGA THCA -0.112 |
hsa-miR-125b-5p | NME2 | 13 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRP; LIHC; LUAD; LUSC; OV; PAAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.079; TCGA BRCA -0.197; TCGA CESC -0.123; TCGA COAD -0.084; TCGA ESCA -0.148; TCGA HNSC -0.157; TCGA KIRP -0.125; TCGA LIHC -0.281; TCGA LUAD -0.154; TCGA LUSC -0.338; TCGA OV -0.119; TCGA PAAD -0.221; TCGA UCEC -0.085 |
hsa-miR-125b-5p | NPM1 | 14 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; LUSC; PRAD; STAD | miRNAWalker2 validate | TCGA BLCA -0.054; TCGA BRCA -0.074; TCGA CESC -0.068; TCGA COAD -0.111; TCGA ESCA -0.09; TCGA HNSC -0.146; TCGA KIRC -0.138; TCGA KIRP -0.107; TCGA LGG -0.189; TCGA LIHC -0.319; TCGA LUAD -0.064; TCGA LUSC -0.116; TCGA PRAD -0.096; TCGA STAD -0.19 |
hsa-miR-125b-5p | NSUN2 | 16 cancers: BLCA; BRCA; CESC; COAD; HNSC; KIRP; LGG; LUAD; LUSC; OV; PAAD; PRAD; SARC; THCA; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.06; TCGA BRCA -0.115; TCGA CESC -0.128; TCGA COAD -0.079; TCGA HNSC -0.144; TCGA KIRP -0.058; TCGA LGG -0.1; TCGA LUAD -0.134; TCGA LUSC -0.13; TCGA OV -0.065; TCGA PAAD -0.187; TCGA PRAD -0.11; TCGA SARC -0.077; TCGA THCA -0.069; TCGA STAD -0.217; TCGA UCEC -0.051 |
hsa-miR-125b-5p | NUP205 | 9 cancers: BLCA; BRCA; COAD; HNSC; LIHC; LUAD; LUSC; PRAD; STAD | miRNAWalker2 validate | TCGA BLCA -0.053; TCGA BRCA -0.081; TCGA COAD -0.098; TCGA HNSC -0.119; TCGA LIHC -0.2; TCGA LUAD -0.122; TCGA LUSC -0.282; TCGA PRAD -0.119; TCGA STAD -0.191 |
hsa-miR-125b-5p | PABPC1 | 14 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; LUSC; PRAD; STAD | miRNAWalker2 validate | TCGA BLCA -0.135; TCGA BRCA -0.058; TCGA CESC -0.162; TCGA COAD -0.082; TCGA ESCA -0.12; TCGA HNSC -0.128; TCGA KIRC -0.102; TCGA KIRP -0.146; TCGA LGG -0.233; TCGA LIHC -0.353; TCGA LUAD -0.152; TCGA LUSC -0.122; TCGA PRAD -0.164; TCGA STAD -0.197 |
hsa-miR-125b-5p | PDZD11 | 10 cancers: BLCA; BRCA; HNSC; LGG; LIHC; LUAD; LUSC; OV; PAAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.075; TCGA BRCA -0.169; TCGA HNSC -0.083; TCGA LGG -0.072; TCGA LIHC -0.211; TCGA LUAD -0.113; TCGA LUSC -0.188; TCGA OV -0.194; TCGA PAAD -0.169; TCGA UCEC -0.064 |
hsa-miR-125b-5p | PIGF | 12 cancers: BLCA; BRCA; CESC; COAD; ESCA; KIRP; LGG; LIHC; LUAD; LUSC; PRAD; STAD | miRNAWalker2 validate; miRTarBase | TCGA BLCA -0.067; TCGA BRCA -0.105; TCGA CESC -0.102; TCGA COAD -0.108; TCGA ESCA -0.178; TCGA KIRP -0.067; TCGA LGG -0.053; TCGA LIHC -0.088; TCGA LUAD -0.138; TCGA LUSC -0.182; TCGA PRAD -0.091; TCGA STAD -0.057 |
hsa-miR-125b-5p | PIP4K2C | 10 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LUAD; LUSC; THCA; STAD | miRNAWalker2 validate | TCGA BLCA -0.069; TCGA BRCA -0.181; TCGA CESC -0.08; TCGA COAD -0.052; TCGA ESCA -0.117; TCGA HNSC -0.155; TCGA LUAD -0.059; TCGA LUSC -0.128; TCGA THCA -0.193; TCGA STAD -0.111 |
hsa-miR-125b-5p | PPAT | 15 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRP; LIHC; LUAD; LUSC; OV; PRAD; THCA; STAD; UCEC | miRNAWalker2 validate; MirTarget; miRNATAP | TCGA BLCA -0.072; TCGA BRCA -0.184; TCGA CESC -0.086; TCGA COAD -0.128; TCGA ESCA -0.145; TCGA HNSC -0.135; TCGA KIRP -0.096; TCGA LIHC -0.203; TCGA LUAD -0.211; TCGA LUSC -0.222; TCGA OV -0.08; TCGA PRAD -0.251; TCGA THCA -0.145; TCGA STAD -0.276; TCGA UCEC -0.082 |
hsa-miR-125b-5p | RPLP0 | 13 cancers: BLCA; CESC; COAD; ESCA; KIRC; KIRP; LGG; LIHC; LUAD; LUSC; PAAD; PRAD; STAD | miRNAWalker2 validate | TCGA BLCA -0.072; TCGA CESC -0.076; TCGA COAD -0.09; TCGA ESCA -0.106; TCGA KIRC -0.166; TCGA KIRP -0.158; TCGA LGG -0.175; TCGA LIHC -0.273; TCGA LUAD -0.115; TCGA LUSC -0.115; TCGA PAAD -0.301; TCGA PRAD -0.086; TCGA STAD -0.138 |
hsa-miR-125b-5p | RPS6KA1 | 11 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; OV; PRAD; THCA; STAD; UCEC | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | TCGA BLCA -0.137; TCGA BRCA -0.138; TCGA CESC -0.077; TCGA COAD -0.105; TCGA ESCA -0.235; TCGA HNSC -0.154; TCGA OV -0.126; TCGA PRAD -0.062; TCGA THCA -0.186; TCGA STAD -0.225; TCGA UCEC -0.217 |
hsa-miR-125b-5p | RPS7 | 11 cancers: BLCA; CESC; HNSC; KIRP; LGG; LIHC; LUAD; LUSC; PAAD; PRAD; STAD | miRNAWalker2 validate | TCGA BLCA -0.081; TCGA CESC -0.071; TCGA HNSC -0.074; TCGA KIRP -0.078; TCGA LGG -0.068; TCGA LIHC -0.284; TCGA LUAD -0.145; TCGA LUSC -0.21; TCGA PAAD -0.223; TCGA PRAD -0.142; TCGA STAD -0.084 |
hsa-miR-125b-5p | SAMD10 | 10 cancers: BLCA; BRCA; KIRP; LGG; LIHC; LUAD; PAAD; SARC; STAD; UCEC | miRNAWalker2 validate; MirTarget; miRNATAP | TCGA BLCA -0.221; TCGA BRCA -0.297; TCGA KIRP -0.106; TCGA LGG -0.265; TCGA LIHC -0.302; TCGA LUAD -0.111; TCGA PAAD -0.433; TCGA SARC -0.19; TCGA STAD -0.181; TCGA UCEC -0.125 |
hsa-miR-125b-5p | SDHB | 12 cancers: BLCA; BRCA; COAD; ESCA; HNSC; LUAD; LUSC; OV; PRAD; THCA; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.062; TCGA BRCA -0.095; TCGA COAD -0.131; TCGA ESCA -0.158; TCGA HNSC -0.051; TCGA LUAD -0.068; TCGA LUSC -0.104; TCGA OV -0.166; TCGA PRAD -0.122; TCGA THCA -0.139; TCGA STAD -0.106; TCGA UCEC -0.141 |
hsa-miR-125b-5p | SLC19A1 | 11 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LGG; PAAD; THCA; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.129; TCGA BRCA -0.314; TCGA CESC -0.242; TCGA COAD -0.112; TCGA ESCA -0.271; TCGA HNSC -0.16; TCGA LGG -0.168; TCGA PAAD -0.307; TCGA THCA -0.302; TCGA STAD -0.222; TCGA UCEC -0.08 |
hsa-miR-125b-5p | SLC25A1 | 13 cancers: BLCA; BRCA; CESC; COAD; HNSC; LGG; LUSC; OV; PAAD; SARC; THCA; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.13; TCGA BRCA -0.106; TCGA CESC -0.065; TCGA COAD -0.087; TCGA HNSC -0.095; TCGA LGG -0.225; TCGA LUSC -0.2; TCGA OV -0.121; TCGA PAAD -0.261; TCGA SARC -0.091; TCGA THCA -0.079; TCGA STAD -0.1; TCGA UCEC -0.125 |
hsa-miR-125b-5p | SMARCD2 | 13 cancers: BLCA; BRCA; COAD; ESCA; KIRP; LUAD; LUSC; OV; PAAD; PRAD; THCA; STAD; UCEC | miRNAWalker2 validate; miRNATAP | TCGA BLCA -0.066; TCGA BRCA -0.133; TCGA COAD -0.081; TCGA ESCA -0.114; TCGA KIRP -0.148; TCGA LUAD -0.088; TCGA LUSC -0.164; TCGA OV -0.108; TCGA PAAD -0.13; TCGA PRAD -0.063; TCGA THCA -0.1; TCGA STAD -0.126; TCGA UCEC -0.052 |
hsa-miR-125b-5p | SNRPB | 13 cancers: BLCA; BRCA; ESCA; HNSC; KIRP; LGG; LIHC; LUAD; LUSC; OV; PAAD; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.066; TCGA BRCA -0.326; TCGA ESCA -0.137; TCGA HNSC -0.164; TCGA KIRP -0.102; TCGA LGG -0.094; TCGA LIHC -0.357; TCGA LUAD -0.141; TCGA LUSC -0.224; TCGA OV -0.115; TCGA PAAD -0.346; TCGA STAD -0.139; TCGA UCEC -0.137 |
hsa-miR-125b-5p | STRN3 | 9 cancers: BLCA; CESC; COAD; HNSC; LUAD; LUSC; PRAD; SARC; THCA | miRNAWalker2 validate | TCGA BLCA -0.06; TCGA CESC -0.062; TCGA COAD -0.123; TCGA HNSC -0.226; TCGA LUAD -0.126; TCGA LUSC -0.141; TCGA PRAD -0.118; TCGA SARC -0.129; TCGA THCA -0.07 |
hsa-miR-125b-5p | TDG | 14 cancers: BLCA; BRCA; CESC; COAD; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; LUSC; PRAD; STAD; UCEC | miRNAWalker2 validate; miRNATAP | TCGA BLCA -0.141; TCGA BRCA -0.065; TCGA CESC -0.077; TCGA COAD -0.115; TCGA HNSC -0.175; TCGA KIRC -0.12; TCGA KIRP -0.09; TCGA LGG -0.134; TCGA LIHC -0.201; TCGA LUAD -0.264; TCGA LUSC -0.213; TCGA PRAD -0.249; TCGA STAD -0.197; TCGA UCEC -0.069 |
hsa-miR-125b-5p | THUMPD3 | 11 cancers: BLCA; BRCA; COAD; ESCA; LIHC; LUAD; LUSC; PRAD; SARC; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.074; TCGA BRCA -0.09; TCGA COAD -0.102; TCGA ESCA -0.073; TCGA LIHC -0.084; TCGA LUAD -0.086; TCGA LUSC -0.158; TCGA PRAD -0.065; TCGA SARC -0.097; TCGA STAD -0.107; TCGA UCEC -0.068 |
hsa-miR-125b-5p | UBA6 | 9 cancers: BLCA; COAD; HNSC; KIRC; KIRP; LUAD; LUSC; PRAD; STAD | miRNAWalker2 validate | TCGA BLCA -0.144; TCGA COAD -0.115; TCGA HNSC -0.245; TCGA KIRC -0.084; TCGA KIRP -0.066; TCGA LUAD -0.058; TCGA LUSC -0.154; TCGA PRAD -0.076; TCGA STAD -0.227 |
hsa-miR-125b-5p | ULK3 | 9 cancers: BLCA; BRCA; COAD; ESCA; KIRC; LUSC; PRAD; SARC; STAD | miRNAWalker2 validate | TCGA BLCA -0.135; TCGA BRCA -0.241; TCGA COAD -0.075; TCGA ESCA -0.098; TCGA KIRC -0.106; TCGA LUSC -0.165; TCGA PRAD -0.08; TCGA SARC -0.129; TCGA STAD -0.079 |
hsa-miR-125b-5p | UNG | 10 cancers: BLCA; BRCA; COAD; LIHC; LUAD; LUSC; PAAD; PRAD; THCA; STAD | miRNAWalker2 validate | TCGA BLCA -0.079; TCGA BRCA -0.158; TCGA COAD -0.111; TCGA LIHC -0.09; TCGA LUAD -0.158; TCGA LUSC -0.247; TCGA PAAD -0.133; TCGA PRAD -0.153; TCGA THCA -0.126; TCGA STAD -0.165 |
hsa-miR-125b-5p | VDAC1 | 15 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LIHC; LUAD; LUSC; OV; PAAD; PRAD; THCA; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.11; TCGA BRCA -0.149; TCGA CESC -0.122; TCGA COAD -0.074; TCGA ESCA -0.277; TCGA HNSC -0.095; TCGA LIHC -0.194; TCGA LUAD -0.116; TCGA LUSC -0.154; TCGA OV -0.105; TCGA PAAD -0.131; TCGA PRAD -0.09; TCGA THCA -0.077; TCGA STAD -0.164; TCGA UCEC -0.134 |
hsa-miR-125b-5p | ZDHHC5 | 9 cancers: BLCA; BRCA; COAD; ESCA; HNSC; KIRP; LUSC; OV; STAD | miRNAWalker2 validate | TCGA BLCA -0.093; TCGA BRCA -0.05; TCGA COAD -0.081; TCGA ESCA -0.072; TCGA HNSC -0.127; TCGA KIRP -0.094; TCGA LUSC -0.095; TCGA OV -0.058; TCGA STAD -0.101 |
hsa-miR-125b-5p | PPP1CA | 14 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRP; LIHC; LUAD; LUSC; OV; PAAD; STAD; UCEC | miRTarBase | TCGA BLCA -0.08; TCGA BRCA -0.295; TCGA CESC -0.076; TCGA COAD -0.102; TCGA ESCA -0.128; TCGA HNSC -0.172; TCGA KIRP -0.058; TCGA LIHC -0.112; TCGA LUAD -0.073; TCGA LUSC -0.098; TCGA OV -0.203; TCGA PAAD -0.197; TCGA STAD -0.115; TCGA UCEC -0.14 |
hsa-miR-125b-5p | PRRC1 | 10 cancers: BLCA; BRCA; COAD; ESCA; LGG; LIHC; LUAD; PRAD; THCA; STAD | MirTarget | TCGA BLCA -0.067; TCGA BRCA -0.052; TCGA COAD -0.07; TCGA ESCA -0.128; TCGA LGG -0.128; TCGA LIHC -0.088; TCGA LUAD -0.103; TCGA PRAD -0.161; TCGA THCA -0.08; TCGA STAD -0.15 |
hsa-miR-125b-5p | ZSCAN29 | 11 cancers: BLCA; ESCA; HNSC; KIRC; LGG; LIHC; LUAD; LUSC; PRAD; SARC; STAD | MirTarget; miRNATAP | TCGA BLCA -0.152; TCGA ESCA -0.149; TCGA HNSC -0.06; TCGA KIRC -0.134; TCGA LGG -0.072; TCGA LIHC -0.068; TCGA LUAD -0.125; TCGA LUSC -0.155; TCGA PRAD -0.11; TCGA SARC -0.055; TCGA STAD -0.086 |
hsa-miR-125b-5p | MMP15 | 11 cancers: BLCA; BRCA; CESC; COAD; ESCA; LGG; LUSC; PRAD; THCA; STAD; UCEC | MirTarget | TCGA BLCA -0.2; TCGA BRCA -0.077; TCGA CESC -0.255; TCGA COAD -0.1; TCGA ESCA -0.426; TCGA LGG -0.412; TCGA LUSC -0.21; TCGA PRAD -0.157; TCGA THCA -0.344; TCGA STAD -0.191; TCGA UCEC -0.185 |
hsa-miR-125b-5p | SUV39H1 | 15 cancers: BLCA; BRCA; COAD; ESCA; KIRC; LGG; LIHC; LUAD; LUSC; OV; PAAD; SARC; THCA; STAD; UCEC | MirTarget; miRNATAP | TCGA BLCA -0.067; TCGA BRCA -0.181; TCGA COAD -0.089; TCGA ESCA -0.115; TCGA KIRC -0.098; TCGA LGG -0.157; TCGA LIHC -0.13; TCGA LUAD -0.111; TCGA LUSC -0.276; TCGA OV -0.158; TCGA PAAD -0.238; TCGA SARC -0.195; TCGA THCA -0.055; TCGA STAD -0.142; TCGA UCEC -0.079 |
hsa-miR-125b-5p | PPIF | 15 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LGG; LUAD; LUSC; OV; PAAD; PRAD; THCA; STAD; UCEC | MirTarget | TCGA BLCA -0.099; TCGA BRCA -0.179; TCGA CESC -0.085; TCGA COAD -0.1; TCGA ESCA -0.171; TCGA HNSC -0.391; TCGA LGG -0.22; TCGA LUAD -0.145; TCGA LUSC -0.31; TCGA OV -0.18; TCGA PAAD -0.295; TCGA PRAD -0.106; TCGA THCA -0.495; TCGA STAD -0.22; TCGA UCEC -0.171 |
hsa-miR-125b-5p | DRAM2 | 11 cancers: BLCA; CESC; COAD; ESCA; KIRC; LIHC; LUAD; OV; SARC; THCA; UCEC | MirTarget; miRNATAP | TCGA BLCA -0.067; TCGA CESC -0.055; TCGA COAD -0.056; TCGA ESCA -0.124; TCGA KIRC -0.068; TCGA LIHC -0.148; TCGA LUAD -0.071; TCGA OV -0.159; TCGA SARC -0.099; TCGA THCA -0.131; TCGA UCEC -0.108 |
hsa-miR-125b-5p | NUP210 | 12 cancers: BLCA; BRCA; CESC; LGG; LIHC; LUAD; LUSC; OV; PRAD; SARC; THCA; UCEC | MirTarget; miRNATAP | TCGA BLCA -0.121; TCGA BRCA -0.466; TCGA CESC -0.087; TCGA LGG -0.235; TCGA LIHC -0.373; TCGA LUAD -0.261; TCGA LUSC -0.258; TCGA OV -0.194; TCGA PRAD -0.36; TCGA SARC -0.536; TCGA THCA -0.292; TCGA UCEC -0.219 |
hsa-miR-125b-5p | RFC5 | 12 cancers: BLCA; BRCA; COAD; KIRP; LIHC; LUAD; LUSC; PAAD; PRAD; SARC; THCA; STAD | MirTarget | TCGA BLCA -0.105; TCGA BRCA -0.171; TCGA COAD -0.166; TCGA KIRP -0.135; TCGA LIHC -0.183; TCGA LUAD -0.208; TCGA LUSC -0.268; TCGA PAAD -0.173; TCGA PRAD -0.159; TCGA SARC -0.078; TCGA THCA -0.118; TCGA STAD -0.207 |
hsa-miR-125b-5p | OVOL1 | 12 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LUAD; LUSC; OV; PRAD; STAD; UCEC | MirTarget | TCGA BLCA -0.442; TCGA BRCA -0.359; TCGA CESC -0.199; TCGA COAD -0.096; TCGA ESCA -0.439; TCGA HNSC -0.466; TCGA LUAD -0.204; TCGA LUSC -0.531; TCGA OV -0.294; TCGA PRAD -0.363; TCGA STAD -0.305; TCGA UCEC -0.291 |
hsa-miR-125b-5p | CSNK2A1 | 11 cancers: BLCA; BRCA; ESCA; HNSC; LGG; LIHC; LUAD; LUSC; PRAD; THCA; STAD | MirTarget; miRNATAP | TCGA BLCA -0.052; TCGA BRCA -0.069; TCGA ESCA -0.144; TCGA HNSC -0.074; TCGA LGG -0.087; TCGA LIHC -0.149; TCGA LUAD -0.08; TCGA LUSC -0.096; TCGA PRAD -0.169; TCGA THCA -0.102; TCGA STAD -0.128 |
hsa-miR-125b-5p | DUS1L | 16 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRC; KIRP; LIHC; LUAD; LUSC; OV; PAAD; THCA; STAD; UCEC | MirTarget | TCGA BLCA -0.147; TCGA BRCA -0.297; TCGA CESC -0.143; TCGA COAD -0.08; TCGA ESCA -0.279; TCGA HNSC -0.12; TCGA KIRC -0.09; TCGA KIRP -0.086; TCGA LIHC -0.104; TCGA LUAD -0.13; TCGA LUSC -0.368; TCGA OV -0.175; TCGA PAAD -0.449; TCGA THCA -0.089; TCGA STAD -0.152; TCGA UCEC -0.217 |
hsa-miR-125b-5p | IER3IP1 | 12 cancers: BLCA; BRCA; COAD; LGG; LIHC; LUAD; LUSC; OV; PAAD; PRAD; STAD; UCEC | MirTarget | TCGA BLCA -0.06; TCGA BRCA -0.189; TCGA COAD -0.122; TCGA LGG -0.105; TCGA LIHC -0.133; TCGA LUAD -0.189; TCGA LUSC -0.197; TCGA OV -0.166; TCGA PAAD -0.118; TCGA PRAD -0.101; TCGA STAD -0.157; TCGA UCEC -0.123 |
hsa-miR-125b-5p | SIRT7 | 15 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRC; KIRP; LGG; LIHC; LUSC; OV; PAAD; STAD; UCEC | MirTarget | TCGA BLCA -0.118; TCGA BRCA -0.281; TCGA CESC -0.101; TCGA COAD -0.106; TCGA ESCA -0.248; TCGA HNSC -0.123; TCGA KIRC -0.158; TCGA KIRP -0.158; TCGA LGG -0.108; TCGA LIHC -0.218; TCGA LUSC -0.311; TCGA OV -0.138; TCGA PAAD -0.313; TCGA STAD -0.142; TCGA UCEC -0.15 |
hsa-miR-125b-5p | TSEN54 | 15 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRP; LGG; LIHC; LUAD; LUSC; OV; PAAD; STAD; UCEC | MirTarget | TCGA BLCA -0.087; TCGA BRCA -0.353; TCGA CESC -0.09; TCGA COAD -0.113; TCGA ESCA -0.255; TCGA HNSC -0.079; TCGA KIRP -0.09; TCGA LGG -0.169; TCGA LIHC -0.305; TCGA LUAD -0.147; TCGA LUSC -0.31; TCGA OV -0.128; TCGA PAAD -0.389; TCGA STAD -0.16; TCGA UCEC -0.112 |
hsa-miR-125b-5p | BDH1 | 13 cancers: BLCA; BRCA; COAD; ESCA; HNSC; LUAD; LUSC; OV; PAAD; SARC; THCA; STAD; UCEC | MirTarget | TCGA BLCA -0.167; TCGA BRCA -0.317; TCGA COAD -0.125; TCGA ESCA -0.245; TCGA HNSC -0.164; TCGA LUAD -0.168; TCGA LUSC -0.472; TCGA OV -0.147; TCGA PAAD -0.302; TCGA SARC -0.512; TCGA THCA -0.294; TCGA STAD -0.261; TCGA UCEC -0.152 |
hsa-miR-125b-5p | LRRC8B | 9 cancers: BLCA; COAD; ESCA; LUAD; PRAD; SARC; THCA; STAD; UCEC | MirTarget; miRNATAP | TCGA BLCA -0.114; TCGA COAD -0.112; TCGA ESCA -0.138; TCGA LUAD -0.136; TCGA PRAD -0.255; TCGA SARC -0.305; TCGA THCA -0.073; TCGA STAD -0.272; TCGA UCEC -0.085 |
hsa-miR-125b-5p | DLD | 11 cancers: BLCA; COAD; ESCA; LUAD; LUSC; OV; PRAD; SARC; THCA; STAD; UCEC | MirTarget | TCGA BLCA -0.053; TCGA COAD -0.092; TCGA ESCA -0.077; TCGA LUAD -0.064; TCGA LUSC -0.114; TCGA OV -0.062; TCGA PRAD -0.075; TCGA SARC -0.055; TCGA THCA -0.348; TCGA STAD -0.15; TCGA UCEC -0.086 |
hsa-miR-125b-5p | SMG5 | 12 cancers: BLCA; BRCA; CESC; ESCA; HNSC; LIHC; LUAD; LUSC; PAAD; SARC; STAD; UCEC | MirTarget | TCGA BLCA -0.082; TCGA BRCA -0.181; TCGA CESC -0.059; TCGA ESCA -0.135; TCGA HNSC -0.104; TCGA LIHC -0.36; TCGA LUAD -0.119; TCGA LUSC -0.099; TCGA PAAD -0.161; TCGA SARC -0.128; TCGA STAD -0.053; TCGA UCEC -0.12 |
hsa-miR-125b-5p | SEMA4B | 11 cancers: BLCA; BRCA; COAD; HNSC; KIRC; KIRP; LUSC; PRAD; SARC; STAD; UCEC | MirTarget | TCGA BLCA -0.22; TCGA BRCA -0.116; TCGA COAD -0.126; TCGA HNSC -0.239; TCGA KIRC -0.31; TCGA KIRP -0.13; TCGA LUSC -0.297; TCGA PRAD -0.096; TCGA SARC -0.428; TCGA STAD -0.11; TCGA UCEC -0.091 |
hsa-miR-125b-5p | ESRRA | 12 cancers: BLCA; BRCA; CESC; COAD; ESCA; LGG; LUSC; OV; PAAD; THCA; STAD; UCEC | MirTarget; miRNATAP | TCGA BLCA -0.159; TCGA BRCA -0.152; TCGA CESC -0.121; TCGA COAD -0.108; TCGA ESCA -0.308; TCGA LGG -0.199; TCGA LUSC -0.286; TCGA OV -0.175; TCGA PAAD -0.248; TCGA THCA -0.338; TCGA STAD -0.185; TCGA UCEC -0.16 |
hsa-miR-125b-5p | TIMM17B | 11 cancers: BLCA; BRCA; LGG; LIHC; LUAD; LUSC; OV; PAAD; SARC; THCA; UCEC | MirTarget | TCGA BLCA -0.068; TCGA BRCA -0.34; TCGA LGG -0.136; TCGA LIHC -0.198; TCGA LUAD -0.143; TCGA LUSC -0.19; TCGA OV -0.178; TCGA PAAD -0.337; TCGA SARC -0.128; TCGA THCA -0.27; TCGA UCEC -0.1 |
hsa-miR-125b-5p | SLC26A6 | 16 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRP; LGG; LIHC; LUAD; LUSC; OV; PAAD; PRAD; SARC; UCEC | MirTarget | TCGA BLCA -0.089; TCGA BRCA -0.279; TCGA CESC -0.243; TCGA COAD -0.101; TCGA ESCA -0.369; TCGA HNSC -0.222; TCGA KIRP -0.128; TCGA LGG -0.202; TCGA LIHC -0.637; TCGA LUAD -0.128; TCGA LUSC -0.329; TCGA OV -0.232; TCGA PAAD -0.326; TCGA PRAD -0.263; TCGA SARC -0.132; TCGA UCEC -0.24 |
hsa-miR-125b-5p | B3GNT3 | 10 cancers: BLCA; CESC; COAD; ESCA; HNSC; LIHC; LUSC; OV; STAD; UCEC | MirTarget | TCGA BLCA -0.295; TCGA CESC -0.53; TCGA COAD -0.121; TCGA ESCA -1.091; TCGA HNSC -0.258; TCGA LIHC -0.822; TCGA LUSC -0.368; TCGA OV -0.215; TCGA STAD -0.218; TCGA UCEC -0.492 |
hsa-miR-125b-5p | VPS4B | 9 cancers: BLCA; COAD; HNSC; LGG; LUAD; LUSC; PRAD; THCA; STAD | MirTarget; miRNATAP | TCGA BLCA -0.062; TCGA COAD -0.133; TCGA HNSC -0.066; TCGA LGG -0.063; TCGA LUAD -0.05; TCGA LUSC -0.099; TCGA PRAD -0.085; TCGA THCA -0.065; TCGA STAD -0.158 |
hsa-miR-125b-5p | DHX33 | 10 cancers: BLCA; CESC; COAD; ESCA; HNSC; LUAD; LUSC; PRAD; THCA; STAD | MirTarget; miRNATAP | TCGA BLCA -0.159; TCGA CESC -0.12; TCGA COAD -0.087; TCGA ESCA -0.12; TCGA HNSC -0.118; TCGA LUAD -0.069; TCGA LUSC -0.213; TCGA PRAD -0.276; TCGA THCA -0.267; TCGA STAD -0.138 |
hsa-miR-125b-5p | NBEAL2 | 9 cancers: BLCA; BRCA; ESCA; LIHC; LUSC; PRAD; SARC; STAD; UCEC | MirTarget; miRNATAP | TCGA BLCA -0.105; TCGA BRCA -0.125; TCGA ESCA -0.289; TCGA LIHC -0.224; TCGA LUSC -0.114; TCGA PRAD -0.241; TCGA SARC -0.152; TCGA STAD -0.225; TCGA UCEC -0.109 |
hsa-miR-125b-5p | TRAPPC6B | 10 cancers: BLCA; COAD; HNSC; LGG; LUAD; LUSC; OV; PRAD; SARC; STAD | MirTarget; miRNATAP | TCGA BLCA -0.07; TCGA COAD -0.063; TCGA HNSC -0.102; TCGA LGG -0.091; TCGA LUAD -0.093; TCGA LUSC -0.101; TCGA OV -0.06; TCGA PRAD -0.077; TCGA SARC -0.071; TCGA STAD -0.051 |
hsa-miR-125b-5p | CDC42SE1 | 13 cancers: BLCA; BRCA; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; LUSC; OV; PRAD; STAD; UCEC | MirTarget | TCGA BLCA -0.078; TCGA BRCA -0.105; TCGA HNSC -0.077; TCGA KIRC -0.104; TCGA KIRP -0.066; TCGA LGG -0.163; TCGA LIHC -0.157; TCGA LUAD -0.106; TCGA LUSC -0.106; TCGA OV -0.096; TCGA PRAD -0.181; TCGA STAD -0.057; TCGA UCEC -0.102 |
hsa-miR-125b-5p | SBNO1 | 9 cancers: BLCA; COAD; ESCA; LUAD; LUSC; PRAD; SARC; THCA; STAD | MirTarget; miRNATAP | TCGA BLCA -0.117; TCGA COAD -0.092; TCGA ESCA -0.077; TCGA LUAD -0.14; TCGA LUSC -0.133; TCGA PRAD -0.301; TCGA SARC -0.235; TCGA THCA -0.403; TCGA STAD -0.148 |
hsa-miR-125b-5p | CASP2 | 11 cancers: BLCA; BRCA; COAD; KIRC; KIRP; LGG; LIHC; LUSC; PRAD; THCA; STAD | MirTarget; miRNATAP | TCGA BLCA -0.093; TCGA BRCA -0.084; TCGA COAD -0.078; TCGA KIRC -0.125; TCGA KIRP -0.129; TCGA LGG -0.109; TCGA LIHC -0.257; TCGA LUSC -0.122; TCGA PRAD -0.163; TCGA THCA -0.081; TCGA STAD -0.136 |
hsa-miR-125b-5p | SLC39A9 | 12 cancers: BLCA; BRCA; COAD; ESCA; HNSC; LGG; LUAD; LUSC; PAAD; PRAD; THCA; STAD | MirTarget | TCGA BLCA -0.091; TCGA BRCA -0.069; TCGA COAD -0.108; TCGA ESCA -0.185; TCGA HNSC -0.104; TCGA LGG -0.131; TCGA LUAD -0.096; TCGA LUSC -0.072; TCGA PAAD -0.087; TCGA PRAD -0.144; TCGA THCA -0.179; TCGA STAD -0.164 |
hsa-miR-125b-5p | SLC25A15 | 14 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LGG; LUAD; LUSC; OV; PRAD; THCA; STAD; UCEC | MirTarget | TCGA BLCA -0.093; TCGA BRCA -0.175; TCGA CESC -0.099; TCGA COAD -0.077; TCGA ESCA -0.308; TCGA HNSC -0.128; TCGA LGG -0.278; TCGA LUAD -0.187; TCGA LUSC -0.256; TCGA OV -0.137; TCGA PRAD -0.266; TCGA THCA -0.821; TCGA STAD -0.187; TCGA UCEC -0.109 |
hsa-miR-125b-5p | EAF1 | 14 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LGG; LUAD; OV; PRAD; SARC; THCA; STAD; UCEC | MirTarget; miRNATAP | TCGA BLCA -0.051; TCGA BRCA -0.113; TCGA CESC -0.097; TCGA COAD -0.102; TCGA ESCA -0.236; TCGA HNSC -0.142; TCGA LGG -0.075; TCGA LUAD -0.079; TCGA OV -0.076; TCGA PRAD -0.152; TCGA SARC -0.169; TCGA THCA -0.167; TCGA STAD -0.17; TCGA UCEC -0.077 |
hsa-miR-125b-5p | PPME1 | 10 cancers: BLCA; BRCA; COAD; HNSC; KIRC; KIRP; LIHC; LUAD; LUSC; SARC | MirTarget | TCGA BLCA -0.078; TCGA BRCA -0.168; TCGA COAD -0.062; TCGA HNSC -0.116; TCGA KIRC -0.083; TCGA KIRP -0.092; TCGA LIHC -0.137; TCGA LUAD -0.092; TCGA LUSC -0.219; TCGA SARC -0.061 |
hsa-miR-125b-5p | CPSF6 | 10 cancers: BLCA; BRCA; COAD; KIRP; LGG; LIHC; LUAD; LUSC; PRAD; STAD | MirTarget; miRNATAP | TCGA BLCA -0.075; TCGA BRCA -0.071; TCGA COAD -0.089; TCGA KIRP -0.058; TCGA LGG -0.065; TCGA LIHC -0.207; TCGA LUAD -0.111; TCGA LUSC -0.142; TCGA PRAD -0.142; TCGA STAD -0.116 |
hsa-miR-125b-5p | GRSF1 | 10 cancers: BLCA; BRCA; COAD; ESCA; LUAD; OV; PAAD; PRAD; STAD; UCEC | MirTarget; miRNATAP | TCGA BLCA -0.101; TCGA BRCA -0.098; TCGA COAD -0.102; TCGA ESCA -0.102; TCGA LUAD -0.09; TCGA OV -0.081; TCGA PAAD -0.188; TCGA PRAD -0.095; TCGA STAD -0.166; TCGA UCEC -0.054 |
hsa-miR-125b-5p | TJAP1 | 9 cancers: BLCA; BRCA; ESCA; KIRC; KIRP; LGG; LIHC; LUSC; PAAD | MirTarget | TCGA BLCA -0.073; TCGA BRCA -0.071; TCGA ESCA -0.093; TCGA KIRC -0.207; TCGA KIRP -0.07; TCGA LGG -0.074; TCGA LIHC -0.134; TCGA LUSC -0.156; TCGA PAAD -0.142 |
hsa-miR-125b-5p | MLX | 15 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LGG; LUAD; LUSC; OV; PAAD; PRAD; THCA; STAD; UCEC | MirTarget | TCGA BLCA -0.085; TCGA BRCA -0.064; TCGA CESC -0.052; TCGA COAD -0.122; TCGA ESCA -0.261; TCGA HNSC -0.072; TCGA LGG -0.064; TCGA LUAD -0.1; TCGA LUSC -0.164; TCGA OV -0.165; TCGA PAAD -0.094; TCGA PRAD -0.074; TCGA THCA -0.13; TCGA STAD -0.142; TCGA UCEC -0.085 |
hsa-miR-125b-5p | RIT1 | 9 cancers: BLCA; KIRC; LIHC; LUAD; LUSC; OV; PRAD; SARC; UCEC | MirTarget | TCGA BLCA -0.07; TCGA KIRC -0.299; TCGA LIHC -0.225; TCGA LUAD -0.146; TCGA LUSC -0.344; TCGA OV -0.1; TCGA PRAD -0.102; TCGA SARC -0.11; TCGA UCEC -0.086 |
hsa-miR-125b-5p | CORO2A | 10 cancers: BLCA; BRCA; COAD; ESCA; KIRC; KIRP; LUSC; OV; STAD; UCEC | MirTarget; miRNATAP | TCGA BLCA -0.193; TCGA BRCA -0.238; TCGA COAD -0.107; TCGA ESCA -0.336; TCGA KIRC -0.258; TCGA KIRP -0.204; TCGA LUSC -0.267; TCGA OV -0.188; TCGA STAD -0.296; TCGA UCEC -0.197 |
hsa-miR-125b-5p | MED20 | 13 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LGG; LIHC; LUAD; LUSC; PRAD; THCA; STAD | MirTarget | TCGA BLCA -0.061; TCGA BRCA -0.055; TCGA CESC -0.062; TCGA COAD -0.06; TCGA ESCA -0.179; TCGA HNSC -0.119; TCGA LGG -0.169; TCGA LIHC -0.133; TCGA LUAD -0.094; TCGA LUSC -0.129; TCGA PRAD -0.175; TCGA THCA -0.157; TCGA STAD -0.088 |
hsa-miR-125b-5p | TMEM161B | 11 cancers: BLCA; BRCA; COAD; ESCA; LGG; LUAD; LUSC; PRAD; SARC; THCA; STAD | MirTarget; miRNATAP | TCGA BLCA -0.162; TCGA BRCA -0.055; TCGA COAD -0.143; TCGA ESCA -0.11; TCGA LGG -0.19; TCGA LUAD -0.064; TCGA LUSC -0.09; TCGA PRAD -0.119; TCGA SARC -0.101; TCGA THCA -0.185; TCGA STAD -0.197 |
hsa-miR-125b-5p | NDUFA2 | 9 cancers: BLCA; BRCA; COAD; ESCA; LGG; LUSC; OV; PAAD; UCEC | MirTarget | TCGA BLCA -0.086; TCGA BRCA -0.257; TCGA COAD -0.089; TCGA ESCA -0.137; TCGA LGG -0.09; TCGA LUSC -0.114; TCGA OV -0.193; TCGA PAAD -0.271; TCGA UCEC -0.124 |
hsa-miR-125b-5p | GALNT7 | 11 cancers: BLCA; BRCA; COAD; ESCA; KIRP; LIHC; LUAD; LUSC; PRAD; STAD; UCEC | MirTarget; miRNATAP | TCGA BLCA -0.144; TCGA BRCA -0.248; TCGA COAD -0.144; TCGA ESCA -0.304; TCGA KIRP -0.157; TCGA LIHC -0.172; TCGA LUAD -0.179; TCGA LUSC -0.149; TCGA PRAD -0.148; TCGA STAD -0.253; TCGA UCEC -0.153 |
hsa-miR-125b-5p | ELOVL6 | 9 cancers: BLCA; BRCA; COAD; ESCA; LGG; LUAD; LUSC; PRAD; STAD | MirTarget; miRNATAP | TCGA BLCA -0.193; TCGA BRCA -0.128; TCGA COAD -0.204; TCGA ESCA -0.232; TCGA LGG -0.17; TCGA LUAD -0.212; TCGA LUSC -0.174; TCGA PRAD -0.2; TCGA STAD -0.22 |
hsa-miR-125b-5p | MAP3K10 | 9 cancers: BLCA; BRCA; CESC; KIRC; KIRP; LUSC; PAAD; SARC; THCA | MirTarget; miRNATAP | TCGA BLCA -0.071; TCGA BRCA -0.28; TCGA CESC -0.081; TCGA KIRC -0.1; TCGA KIRP -0.057; TCGA LUSC -0.198; TCGA PAAD -0.201; TCGA SARC -0.136; TCGA THCA -0.132 |
hsa-miR-125b-5p | CLN6 | 16 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRC; LGG; LIHC; LUAD; LUSC; OV; PAAD; SARC; STAD; UCEC | MirTarget | TCGA BLCA -0.079; TCGA BRCA -0.223; TCGA CESC -0.081; TCGA COAD -0.137; TCGA ESCA -0.266; TCGA HNSC -0.084; TCGA KIRC -0.092; TCGA LGG -0.129; TCGA LIHC -0.168; TCGA LUAD -0.094; TCGA LUSC -0.146; TCGA OV -0.133; TCGA PAAD -0.162; TCGA SARC -0.101; TCGA STAD -0.162; TCGA UCEC -0.155 |
hsa-miR-125b-5p | KLC2 | 12 cancers: BLCA; BRCA; CESC; COAD; HNSC; KIRP; LIHC; LUSC; OV; PAAD; SARC; UCEC | MirTarget; miRNATAP | TCGA BLCA -0.093; TCGA BRCA -0.343; TCGA CESC -0.129; TCGA COAD -0.086; TCGA HNSC -0.143; TCGA KIRP -0.073; TCGA LIHC -0.279; TCGA LUSC -0.276; TCGA OV -0.066; TCGA PAAD -0.135; TCGA SARC -0.164; TCGA UCEC -0.064 |
hsa-miR-125b-5p | HAPLN1 | 13 cancers: BLCA; BRCA; CESC; COAD; HNSC; KIRC; KIRP; LGG; LIHC; OV; PAAD; STAD; UCEC | MirTarget; miRNATAP | TCGA BLCA -0.693; TCGA BRCA -0.529; TCGA CESC -0.389; TCGA COAD -0.284; TCGA HNSC -0.429; TCGA KIRC -1.012; TCGA KIRP -0.397; TCGA LGG -0.858; TCGA LIHC -0.368; TCGA OV -0.346; TCGA PAAD -0.734; TCGA STAD -0.638; TCGA UCEC -0.199 |
hsa-miR-125b-5p | CYB561 | 10 cancers: BLCA; BRCA; ESCA; KIRP; LIHC; LUAD; PAAD; THCA; STAD; UCEC | mirMAP | TCGA BLCA -0.092; TCGA BRCA -0.295; TCGA ESCA -0.242; TCGA KIRP -0.058; TCGA LIHC -0.258; TCGA LUAD -0.093; TCGA PAAD -0.323; TCGA THCA -0.252; TCGA STAD -0.181; TCGA UCEC -0.086 |
hsa-miR-125b-5p | DDX11 | 9 cancers: BLCA; BRCA; KIRC; LGG; LIHC; LUAD; LUSC; PAAD; STAD | mirMAP | TCGA BLCA -0.117; TCGA BRCA -0.215; TCGA KIRC -0.261; TCGA LGG -0.271; TCGA LIHC -0.408; TCGA LUAD -0.122; TCGA LUSC -0.316; TCGA PAAD -0.28; TCGA STAD -0.185 |
hsa-miR-125b-5p | WBSCR22 | 10 cancers: BLCA; BRCA; ESCA; LGG; LIHC; LUSC; OV; PAAD; STAD; UCEC | mirMAP | TCGA BLCA -0.059; TCGA BRCA -0.214; TCGA ESCA -0.139; TCGA LGG -0.081; TCGA LIHC -0.1; TCGA LUSC -0.192; TCGA OV -0.073; TCGA PAAD -0.307; TCGA STAD -0.094; TCGA UCEC -0.089 |
hsa-miR-125b-5p | MARK2 | 10 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LIHC; LUSC; PRAD; STAD | mirMAP; miRNATAP | TCGA BLCA -0.09; TCGA BRCA -0.132; TCGA CESC -0.051; TCGA COAD -0.078; TCGA ESCA -0.148; TCGA HNSC -0.073; TCGA LIHC -0.105; TCGA LUSC -0.105; TCGA PRAD -0.076; TCGA STAD -0.103 |
hsa-miR-125b-5p | ATXN7L3 | 10 cancers: BLCA; BRCA; ESCA; HNSC; KIRP; LIHC; LUAD; LUSC; PRAD; STAD | mirMAP | TCGA BLCA -0.115; TCGA BRCA -0.125; TCGA ESCA -0.081; TCGA HNSC -0.101; TCGA KIRP -0.056; TCGA LIHC -0.161; TCGA LUAD -0.079; TCGA LUSC -0.134; TCGA PRAD -0.055; TCGA STAD -0.068 |
hsa-miR-125b-5p | DNAJC5 | 9 cancers: BLCA; BRCA; HNSC; LIHC; OV; PAAD; PRAD; THCA; STAD | mirMAP | TCGA BLCA -0.066; TCGA BRCA -0.138; TCGA HNSC -0.096; TCGA LIHC -0.229; TCGA OV -0.074; TCGA PAAD -0.197; TCGA PRAD -0.089; TCGA THCA -0.077; TCGA STAD -0.066 |
hsa-miR-125b-5p | MOGS | 14 cancers: BLCA; BRCA; CESC; ESCA; HNSC; KIRC; KIRP; LGG; LIHC; LUSC; PAAD; PRAD; STAD; UCEC | mirMAP | TCGA BLCA -0.066; TCGA BRCA -0.217; TCGA CESC -0.128; TCGA ESCA -0.137; TCGA HNSC -0.101; TCGA KIRC -0.181; TCGA KIRP -0.128; TCGA LGG -0.121; TCGA LIHC -0.089; TCGA LUSC -0.22; TCGA PAAD -0.278; TCGA PRAD -0.133; TCGA STAD -0.094; TCGA UCEC -0.091 |
hsa-miR-125b-5p | PIGZ | 11 cancers: BLCA; KIRC; KIRP; LGG; LIHC; LUSC; OV; PAAD; SARC; THCA; UCEC | mirMAP | TCGA BLCA -0.215; TCGA KIRC -0.237; TCGA KIRP -0.156; TCGA LGG -0.175; TCGA LIHC -0.319; TCGA LUSC -0.355; TCGA OV -0.279; TCGA PAAD -0.211; TCGA SARC -0.15; TCGA THCA -0.323; TCGA UCEC -0.23 |
hsa-miR-125b-5p | SLC25A35 | 10 cancers: BLCA; BRCA; ESCA; LGG; LIHC; LUAD; OV; PAAD; SARC; THCA | mirMAP | TCGA BLCA -0.087; TCGA BRCA -0.209; TCGA ESCA -0.112; TCGA LGG -0.1; TCGA LIHC -0.206; TCGA LUAD -0.135; TCGA OV -0.156; TCGA PAAD -0.141; TCGA SARC -0.096; TCGA THCA -0.144 |
hsa-miR-125b-5p | XRCC3 | 15 cancers: BLCA; BRCA; CESC; COAD; HNSC; KIRC; KIRP; LGG; LIHC; LUSC; OV; PAAD; SARC; STAD; UCEC | mirMAP | TCGA BLCA -0.124; TCGA BRCA -0.226; TCGA CESC -0.084; TCGA COAD -0.187; TCGA HNSC -0.178; TCGA KIRC -0.239; TCGA KIRP -0.102; TCGA LGG -0.17; TCGA LIHC -0.375; TCGA LUSC -0.33; TCGA OV -0.083; TCGA PAAD -0.391; TCGA SARC -0.146; TCGA STAD -0.114; TCGA UCEC -0.092 |
hsa-miR-125b-5p | TOMM40 | 12 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LIHC; LUSC; OV; PAAD; STAD; UCEC | mirMAP | TCGA BLCA -0.077; TCGA BRCA -0.289; TCGA CESC -0.107; TCGA COAD -0.124; TCGA ESCA -0.231; TCGA HNSC -0.144; TCGA LIHC -0.289; TCGA LUSC -0.286; TCGA OV -0.112; TCGA PAAD -0.278; TCGA STAD -0.196; TCGA UCEC -0.123 |
hsa-miR-125b-5p | ANKRD52 | 9 cancers: BLCA; BRCA; CESC; COAD; ESCA; LIHC; LUAD; LUSC; THCA | mirMAP | TCGA BLCA -0.079; TCGA BRCA -0.08; TCGA CESC -0.067; TCGA COAD -0.053; TCGA ESCA -0.109; TCGA LIHC -0.387; TCGA LUAD -0.07; TCGA LUSC -0.11; TCGA THCA -0.121 |
hsa-miR-125b-5p | ZBTB7B | 11 cancers: BLCA; BRCA; COAD; ESCA; HNSC; KIRC; LUAD; LUSC; SARC; STAD; UCEC | mirMAP | TCGA BLCA -0.188; TCGA BRCA -0.217; TCGA COAD -0.086; TCGA ESCA -0.151; TCGA HNSC -0.079; TCGA KIRC -0.12; TCGA LUAD -0.094; TCGA LUSC -0.17; TCGA SARC -0.27; TCGA STAD -0.119; TCGA UCEC -0.118 |
hsa-miR-125b-5p | NACC1 | 10 cancers: BLCA; BRCA; CESC; COAD; HNSC; LIHC; LUSC; PAAD; STAD; UCEC | mirMAP | TCGA BLCA -0.112; TCGA BRCA -0.336; TCGA CESC -0.112; TCGA COAD -0.091; TCGA HNSC -0.155; TCGA LIHC -0.138; TCGA LUSC -0.224; TCGA PAAD -0.171; TCGA STAD -0.07; TCGA UCEC -0.065 |
hsa-miR-125b-5p | LRRC14 | 10 cancers: BLCA; BRCA; COAD; LGG; LIHC; LUSC; OV; PAAD; SARC; STAD | mirMAP | TCGA BLCA -0.104; TCGA BRCA -0.211; TCGA COAD -0.08; TCGA LGG -0.131; TCGA LIHC -0.304; TCGA LUSC -0.126; TCGA OV -0.107; TCGA PAAD -0.279; TCGA SARC -0.1; TCGA STAD -0.071 |
hsa-miR-125b-5p | SLC25A10 | 11 cancers: BLCA; BRCA; COAD; ESCA; LUAD; LUSC; OV; PAAD; THCA; STAD; UCEC | mirMAP | TCGA BLCA -0.19; TCGA BRCA -0.322; TCGA COAD -0.177; TCGA ESCA -0.339; TCGA LUAD -0.155; TCGA LUSC -0.334; TCGA OV -0.146; TCGA PAAD -0.459; TCGA THCA -0.081; TCGA STAD -0.18; TCGA UCEC -0.154 |
hsa-miR-125b-5p | TMEM184B | 9 cancers: BLCA; BRCA; CESC; HNSC; KIRC; LGG; LIHC; PAAD; UCEC | mirMAP | TCGA BLCA -0.059; TCGA BRCA -0.11; TCGA CESC -0.059; TCGA HNSC -0.124; TCGA KIRC -0.104; TCGA LGG -0.061; TCGA LIHC -0.199; TCGA PAAD -0.113; TCGA UCEC -0.082 |
hsa-miR-125b-5p | PFDN6 | 13 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LIHC; LUAD; LUSC; OV; PAAD; STAD; UCEC | mirMAP | TCGA BLCA -0.084; TCGA BRCA -0.315; TCGA CESC -0.168; TCGA COAD -0.072; TCGA ESCA -0.171; TCGA HNSC -0.111; TCGA LIHC -0.192; TCGA LUAD -0.125; TCGA LUSC -0.25; TCGA OV -0.109; TCGA PAAD -0.268; TCGA STAD -0.14; TCGA UCEC -0.16 |
hsa-miR-125b-5p | DDR1 | 12 cancers: BLCA; BRCA; COAD; HNSC; KIRP; LGG; LIHC; LUSC; PAAD; PRAD; SARC; STAD | mirMAP | TCGA BLCA -0.196; TCGA BRCA -0.248; TCGA COAD -0.071; TCGA HNSC -0.077; TCGA KIRP -0.116; TCGA LGG -0.145; TCGA LIHC -0.491; TCGA LUSC -0.145; TCGA PAAD -0.178; TCGA PRAD -0.165; TCGA SARC -0.152; TCGA STAD -0.174 |
hsa-miR-125b-5p | NECAB3 | 12 cancers: BLCA; BRCA; ESCA; LGG; LIHC; LUAD; LUSC; PAAD; SARC; THCA; STAD; UCEC | miRNATAP | TCGA BLCA -0.061; TCGA BRCA -0.455; TCGA ESCA -0.104; TCGA LGG -0.142; TCGA LIHC -0.235; TCGA LUAD -0.135; TCGA LUSC -0.17; TCGA PAAD -0.433; TCGA SARC -0.152; TCGA THCA -0.223; TCGA STAD -0.104; TCGA UCEC -0.099 |
hsa-miR-125b-5p | ZFP62 | 11 cancers: BLCA; BRCA; KIRP; LGG; LIHC; LUAD; PAAD; PRAD; SARC; THCA; STAD | miRNATAP | TCGA BLCA -0.211; TCGA BRCA -0.093; TCGA KIRP -0.071; TCGA LGG -0.11; TCGA LIHC -0.2; TCGA LUAD -0.075; TCGA PAAD -0.106; TCGA PRAD -0.136; TCGA SARC -0.104; TCGA THCA -0.086; TCGA STAD -0.125 |
hsa-miR-125b-5p | KIAA1841 | 9 cancers: BLCA; BRCA; KIRC; KIRP; LIHC; LUAD; LUSC; OV; STAD | miRNATAP | TCGA BLCA -0.053; TCGA BRCA -0.155; TCGA KIRC -0.198; TCGA KIRP -0.215; TCGA LIHC -0.437; TCGA LUAD -0.171; TCGA LUSC -0.234; TCGA OV -0.101; TCGA STAD -0.133 |
hsa-miR-125b-5p | YOD1 | 10 cancers: BLCA; CESC; COAD; HNSC; LIHC; LUAD; LUSC; PRAD; SARC; STAD | miRNATAP | TCGA BLCA -0.157; TCGA CESC -0.083; TCGA COAD -0.117; TCGA HNSC -0.15; TCGA LIHC -0.076; TCGA LUAD -0.174; TCGA LUSC -0.179; TCGA PRAD -0.183; TCGA SARC -0.065; TCGA STAD -0.281 |
hsa-miR-125b-5p | KIAA1522 | 10 cancers: BLCA; BRCA; COAD; ESCA; LIHC; LUSC; PRAD; SARC; STAD; UCEC | miRNATAP | TCGA BLCA -0.235; TCGA BRCA -0.204; TCGA COAD -0.093; TCGA ESCA -0.147; TCGA LIHC -0.442; TCGA LUSC -0.119; TCGA PRAD -0.089; TCGA SARC -0.376; TCGA STAD -0.219; TCGA UCEC -0.077 |
hsa-miR-125b-5p | ITCH | 10 cancers: BLCA; CESC; HNSC; LUAD; LUSC; PRAD; SARC; THCA; STAD; UCEC | miRNATAP | TCGA BLCA -0.08; TCGA CESC -0.052; TCGA HNSC -0.083; TCGA LUAD -0.08; TCGA LUSC -0.074; TCGA PRAD -0.132; TCGA SARC -0.085; TCGA THCA -0.129; TCGA STAD -0.097; TCGA UCEC -0.073 |
hsa-miR-125b-5p | AIFM1 | 13 cancers: BLCA; BRCA; COAD; ESCA; LGG; LUAD; LUSC; OV; PAAD; PRAD; THCA; STAD; UCEC | miRNATAP | TCGA BLCA -0.087; TCGA BRCA -0.203; TCGA COAD -0.065; TCGA ESCA -0.223; TCGA LGG -0.059; TCGA LUAD -0.094; TCGA LUSC -0.224; TCGA OV -0.109; TCGA PAAD -0.153; TCGA PRAD -0.106; TCGA THCA -0.274; TCGA STAD -0.213; TCGA UCEC -0.123 |
hsa-miR-125b-5p | HNRNPA2B1 | 10 cancers: BLCA; BRCA; COAD; ESCA; KIRP; LIHC; LUAD; LUSC; PRAD; STAD | miRNATAP | TCGA BLCA -0.057; TCGA BRCA -0.167; TCGA COAD -0.065; TCGA ESCA -0.106; TCGA KIRP -0.05; TCGA LIHC -0.101; TCGA LUAD -0.057; TCGA LUSC -0.158; TCGA PRAD -0.091; TCGA STAD -0.181 |
hsa-miR-125b-5p | FBXL19 | 9 cancers: BLCA; BRCA; CESC; HNSC; KIRC; LGG; LIHC; LUSC; PAAD | miRNATAP | TCGA BLCA -0.111; TCGA BRCA -0.294; TCGA CESC -0.055; TCGA HNSC -0.107; TCGA KIRC -0.099; TCGA LGG -0.174; TCGA LIHC -0.274; TCGA LUSC -0.249; TCGA PAAD -0.129 |
hsa-miR-125b-5p | ZDHHC9 | 14 cancers: BLCA; BRCA; CESC; ESCA; HNSC; KIRC; LGG; LIHC; LUSC; OV; PRAD; THCA; STAD; UCEC | miRNATAP | TCGA BLCA -0.094; TCGA BRCA -0.124; TCGA CESC -0.121; TCGA ESCA -0.301; TCGA HNSC -0.193; TCGA KIRC -0.095; TCGA LGG -0.086; TCGA LIHC -0.134; TCGA LUSC -0.186; TCGA OV -0.073; TCGA PRAD -0.192; TCGA THCA -0.079; TCGA STAD -0.208; TCGA UCEC -0.053 |
hsa-miR-125b-5p | AKAP1 | 10 cancers: BLCA; CESC; ESCA; LUAD; LUSC; OV; PAAD; SARC; THCA; STAD | miRNATAP | TCGA BLCA -0.134; TCGA CESC -0.063; TCGA ESCA -0.357; TCGA LUAD -0.108; TCGA LUSC -0.204; TCGA OV -0.066; TCGA PAAD -0.154; TCGA SARC -0.542; TCGA THCA -0.068; TCGA STAD -0.154 |
hsa-miR-125b-5p | PTPN18 | 10 cancers: BLCA; BRCA; ESCA; KIRC; KIRP; OV; SARC; THCA; STAD; UCEC | miRNATAP | TCGA BLCA -0.077; TCGA BRCA -0.079; TCGA ESCA -0.253; TCGA KIRC -0.164; TCGA KIRP -0.067; TCGA OV -0.077; TCGA SARC -0.13; TCGA THCA -0.152; TCGA STAD -0.062; TCGA UCEC -0.113 |
hsa-miR-125b-5p | JUP | 9 cancers: BLCA; BRCA; ESCA; HNSC; KIRP; LUSC; PAAD; STAD; UCEC | miRNATAP | TCGA BLCA -0.178; TCGA BRCA -0.189; TCGA ESCA -0.231; TCGA HNSC -0.394; TCGA KIRP -0.077; TCGA LUSC -0.377; TCGA PAAD -0.208; TCGA STAD -0.288; TCGA UCEC -0.088 |
hsa-miR-125b-5p | FAM126B | 9 cancers: BLCA; ESCA; HNSC; LUAD; LUSC; PRAD; THCA; STAD; UCEC | miRNATAP | TCGA BLCA -0.097; TCGA ESCA -0.126; TCGA HNSC -0.117; TCGA LUAD -0.178; TCGA LUSC -0.091; TCGA PRAD -0.201; TCGA THCA -0.118; TCGA STAD -0.113; TCGA UCEC -0.071 |
hsa-miR-125b-5p | SOCS4 | 10 cancers: BLCA; COAD; ESCA; HNSC; LUAD; LUSC; PRAD; SARC; THCA; STAD | miRNATAP | TCGA BLCA -0.102; TCGA COAD -0.098; TCGA ESCA -0.082; TCGA HNSC -0.115; TCGA LUAD -0.113; TCGA LUSC -0.093; TCGA PRAD -0.133; TCGA SARC -0.147; TCGA THCA -0.134; TCGA STAD -0.15 |
hsa-miR-125b-5p | GTPBP2 | 16 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRC; KIRP; LGG; LIHC; LUSC; PAAD; PRAD; SARC; STAD; UCEC | miRNATAP | TCGA BLCA -0.12; TCGA BRCA -0.132; TCGA CESC -0.061; TCGA COAD -0.071; TCGA ESCA -0.191; TCGA HNSC -0.068; TCGA KIRC -0.29; TCGA KIRP -0.173; TCGA LGG -0.063; TCGA LIHC -0.24; TCGA LUSC -0.161; TCGA PAAD -0.091; TCGA PRAD -0.143; TCGA SARC -0.062; TCGA STAD -0.084; TCGA UCEC -0.059 |
hsa-miR-125b-5p | ATP13A3 | 12 cancers: BLCA; BRCA; CESC; ESCA; HNSC; KIRC; LUAD; LUSC; PRAD; SARC; STAD; UCEC | miRNATAP | TCGA BLCA -0.108; TCGA BRCA -0.05; TCGA CESC -0.139; TCGA ESCA -0.152; TCGA HNSC -0.225; TCGA KIRC -0.17; TCGA LUAD -0.159; TCGA LUSC -0.314; TCGA PRAD -0.142; TCGA SARC -0.188; TCGA STAD -0.202; TCGA UCEC -0.114 |
hsa-miR-125b-5p | PI4K2B | 11 cancers: BLCA; COAD; ESCA; HNSC; LUAD; OV; PRAD; SARC; THCA; STAD; UCEC | miRNATAP | TCGA BLCA -0.072; TCGA COAD -0.108; TCGA ESCA -0.126; TCGA HNSC -0.058; TCGA LUAD -0.13; TCGA OV -0.173; TCGA PRAD -0.205; TCGA SARC -0.175; TCGA THCA -0.172; TCGA STAD -0.291; TCGA UCEC -0.095 |
hsa-miR-125b-5p | PIK3C2B | 9 cancers: BLCA; COAD; ESCA; KIRC; KIRP; LGG; PRAD; THCA; STAD | miRNATAP | TCGA BLCA -0.221; TCGA COAD -0.064; TCGA ESCA -0.219; TCGA KIRC -0.164; TCGA KIRP -0.142; TCGA LGG -0.15; TCGA PRAD -0.14; TCGA THCA -0.354; TCGA STAD -0.101 |
hsa-miR-125b-5p | FMR1 | 9 cancers: BLCA; BRCA; LGG; LUAD; LUSC; OV; PRAD; SARC; STAD | miRNATAP | TCGA BLCA -0.102; TCGA BRCA -0.055; TCGA LGG -0.089; TCGA LUAD -0.11; TCGA LUSC -0.11; TCGA OV -0.074; TCGA PRAD -0.085; TCGA SARC -0.096; TCGA STAD -0.116 |
hsa-miR-125b-5p | TUBG1 | 14 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LIHC; LUAD; LUSC; OV; PAAD; SARC; STAD; UCEC | miRNATAP | TCGA BLCA -0.121; TCGA BRCA -0.288; TCGA CESC -0.054; TCGA COAD -0.128; TCGA ESCA -0.154; TCGA HNSC -0.168; TCGA LIHC -0.289; TCGA LUAD -0.142; TCGA LUSC -0.329; TCGA OV -0.156; TCGA PAAD -0.283; TCGA SARC -0.233; TCGA STAD -0.117; TCGA UCEC -0.089 |
hsa-miR-125b-5p | BAZ2A | 10 cancers: BLCA; CESC; HNSC; KIRC; KIRP; LIHC; LUAD; LUSC; PRAD; STAD | miRNATAP | TCGA BLCA -0.096; TCGA CESC -0.122; TCGA HNSC -0.139; TCGA KIRC -0.157; TCGA KIRP -0.108; TCGA LIHC -0.213; TCGA LUAD -0.115; TCGA LUSC -0.081; TCGA PRAD -0.236; TCGA STAD -0.062 |
hsa-miR-125b-5p | HMGB3 | 13 cancers: BLCA; BRCA; CESC; COAD; HNSC; LGG; LIHC; LUAD; LUSC; OV; PAAD; STAD; UCEC | miRNATAP | TCGA BLCA -0.143; TCGA BRCA -0.462; TCGA CESC -0.138; TCGA COAD -0.088; TCGA HNSC -0.203; TCGA LGG -0.293; TCGA LIHC -0.137; TCGA LUAD -0.341; TCGA LUSC -0.565; TCGA OV -0.1; TCGA PAAD -0.3; TCGA STAD -0.297; TCGA UCEC -0.118 |
hsa-miR-125b-5p | AURKB | 16 cancers: BRCA; CESC; COAD; ESCA; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; LUSC; OV; PAAD; PRAD; STAD; UCEC | miRNAWalker2 validate | TCGA BRCA -0.695; TCGA CESC -0.112; TCGA COAD -0.165; TCGA ESCA -0.209; TCGA HNSC -0.217; TCGA KIRC -0.684; TCGA KIRP -0.46; TCGA LGG -0.492; TCGA LIHC -1.08; TCGA LUAD -0.353; TCGA LUSC -0.63; TCGA OV -0.263; TCGA PAAD -0.449; TCGA PRAD -0.194; TCGA STAD -0.351; TCGA UCEC -0.33 |
hsa-miR-125b-5p | B4GALT3 | 12 cancers: BRCA; CESC; ESCA; HNSC; LGG; LIHC; LUAD; LUSC; OV; PAAD; STAD; UCEC | miRNAWalker2 validate | TCGA BRCA -0.234; TCGA CESC -0.055; TCGA ESCA -0.136; TCGA HNSC -0.08; TCGA LGG -0.155; TCGA LIHC -0.227; TCGA LUAD -0.119; TCGA LUSC -0.144; TCGA OV -0.065; TCGA PAAD -0.19; TCGA STAD -0.104; TCGA UCEC -0.088 |
hsa-miR-125b-5p | BBC3 | 9 cancers: BRCA; ESCA; KIRC; KIRP; LGG; LIHC; PAAD; STAD; UCEC | miRNAWalker2 validate; miRTarBase | TCGA BRCA -0.362; TCGA ESCA -0.133; TCGA KIRC -0.347; TCGA KIRP -0.161; TCGA LGG -0.104; TCGA LIHC -0.252; TCGA PAAD -0.399; TCGA STAD -0.115; TCGA UCEC -0.086 |
hsa-miR-125b-5p | CCNE1 | 13 cancers: BRCA; CESC; COAD; ESCA; HNSC; KIRP; LIHC; LUAD; LUSC; OV; SARC; STAD; UCEC | miRNAWalker2 validate | TCGA BRCA -0.382; TCGA CESC -0.128; TCGA COAD -0.153; TCGA ESCA -0.262; TCGA HNSC -0.277; TCGA KIRP -0.236; TCGA LIHC -0.798; TCGA LUAD -0.213; TCGA LUSC -0.583; TCGA OV -0.273; TCGA SARC -0.31; TCGA STAD -0.329; TCGA UCEC -0.255 |
hsa-miR-125b-5p | CHPF2 | 9 cancers: BRCA; CESC; HNSC; KIRC; KIRP; LIHC; PAAD; PRAD; UCEC | miRNAWalker2 validate | TCGA BRCA -0.136; TCGA CESC -0.101; TCGA HNSC -0.144; TCGA KIRC -0.114; TCGA KIRP -0.108; TCGA LIHC -0.13; TCGA PAAD -0.214; TCGA PRAD -0.111; TCGA UCEC -0.083 |
hsa-miR-125b-5p | E2F2 | 13 cancers: BRCA; COAD; ESCA; KIRC; KIRP; LIHC; LUAD; LUSC; OV; PRAD; SARC; STAD; UCEC | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | TCGA BRCA -0.494; TCGA COAD -0.236; TCGA ESCA -0.216; TCGA KIRC -0.625; TCGA KIRP -0.359; TCGA LIHC -0.8; TCGA LUAD -0.257; TCGA LUSC -0.333; TCGA OV -0.141; TCGA PRAD -0.292; TCGA SARC -0.194; TCGA STAD -0.435; TCGA UCEC -0.307 |
hsa-miR-125b-5p | EDEM1 | 10 cancers: BRCA; CESC; COAD; ESCA; KIRC; KIRP; PRAD; SARC; STAD; UCEC | miRNAWalker2 validate; MirTarget; miRNATAP | TCGA BRCA -0.053; TCGA CESC -0.072; TCGA COAD -0.057; TCGA ESCA -0.103; TCGA KIRC -0.119; TCGA KIRP -0.065; TCGA PRAD -0.12; TCGA SARC -0.097; TCGA STAD -0.125; TCGA UCEC -0.083 |
hsa-miR-125b-5p | EIF4EBP1 | 13 cancers: BRCA; COAD; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; LUSC; PAAD; THCA; STAD; UCEC | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | TCGA BRCA -0.288; TCGA COAD -0.14; TCGA HNSC -0.246; TCGA KIRC -0.329; TCGA KIRP -0.129; TCGA LGG -0.308; TCGA LIHC -0.117; TCGA LUAD -0.144; TCGA LUSC -0.502; TCGA PAAD -0.427; TCGA THCA -0.168; TCGA STAD -0.107; TCGA UCEC -0.145 |
hsa-miR-125b-5p | GPRIN1 | 10 cancers: BRCA; COAD; HNSC; KIRC; KIRP; LGG; LIHC; LUSC; STAD; UCEC | miRNAWalker2 validate | TCGA BRCA -0.535; TCGA COAD -0.131; TCGA HNSC -0.487; TCGA KIRC -0.47; TCGA KIRP -0.433; TCGA LGG -0.466; TCGA LIHC -0.766; TCGA LUSC -0.373; TCGA STAD -0.163; TCGA UCEC -0.209 |
hsa-miR-125b-5p | HDGF | 13 cancers: BRCA; CESC; ESCA; HNSC; KIRP; LIHC; LUAD; LUSC; OV; PAAD; PRAD; STAD; UCEC | miRNAWalker2 validate | TCGA BRCA -0.256; TCGA CESC -0.098; TCGA ESCA -0.181; TCGA HNSC -0.113; TCGA KIRP -0.105; TCGA LIHC -0.083; TCGA LUAD -0.174; TCGA LUSC -0.209; TCGA OV -0.066; TCGA PAAD -0.128; TCGA PRAD -0.077; TCGA STAD -0.163; TCGA UCEC -0.128 |
hsa-miR-125b-5p | HMGA1 | 11 cancers: BRCA; CESC; COAD; ESCA; HNSC; KIRP; LIHC; LUSC; PAAD; STAD; UCEC | miRNAWalker2 validate; miRTarBase | TCGA BRCA -0.339; TCGA CESC -0.175; TCGA COAD -0.182; TCGA ESCA -0.277; TCGA HNSC -0.205; TCGA KIRP -0.185; TCGA LIHC -0.65; TCGA LUSC -0.368; TCGA PAAD -0.316; TCGA STAD -0.216; TCGA UCEC -0.218 |
hsa-miR-125b-5p | HSPBP1 | 10 cancers: BRCA; CESC; COAD; ESCA; HNSC; LIHC; LUSC; PAAD; STAD; UCEC | miRNAWalker2 validate | TCGA BRCA -0.268; TCGA CESC -0.095; TCGA COAD -0.077; TCGA ESCA -0.123; TCGA HNSC -0.067; TCGA LIHC -0.12; TCGA LUSC -0.097; TCGA PAAD -0.43; TCGA STAD -0.078; TCGA UCEC -0.057 |
hsa-miR-125b-5p | KPNB1 | 13 cancers: BRCA; CESC; COAD; ESCA; HNSC; LIHC; LUAD; LUSC; PRAD; SARC; THCA; STAD; UCEC | miRNAWalker2 validate | TCGA BRCA -0.098; TCGA CESC -0.07; TCGA COAD -0.113; TCGA ESCA -0.074; TCGA HNSC -0.096; TCGA LIHC -0.175; TCGA LUAD -0.145; TCGA LUSC -0.163; TCGA PRAD -0.141; TCGA SARC -0.086; TCGA THCA -0.13; TCGA STAD -0.12; TCGA UCEC -0.055 |
hsa-miR-125b-5p | LACTB | 12 cancers: BRCA; CESC; COAD; ESCA; HNSC; LUSC; OV; PRAD; SARC; THCA; STAD; UCEC | miRNAWalker2 validate; MirTarget | TCGA BRCA -0.078; TCGA CESC -0.156; TCGA COAD -0.054; TCGA ESCA -0.187; TCGA HNSC -0.177; TCGA LUSC -0.097; TCGA OV -0.17; TCGA PRAD -0.236; TCGA SARC -0.163; TCGA THCA -0.195; TCGA STAD -0.099; TCGA UCEC -0.186 |
hsa-miR-125b-5p | MRTO4 | 13 cancers: BRCA; CESC; COAD; ESCA; HNSC; KIRC; LIHC; LUAD; LUSC; OV; PAAD; STAD; UCEC | miRNAWalker2 validate | TCGA BRCA -0.106; TCGA CESC -0.082; TCGA COAD -0.104; TCGA ESCA -0.115; TCGA HNSC -0.173; TCGA KIRC -0.073; TCGA LIHC -0.202; TCGA LUAD -0.077; TCGA LUSC -0.116; TCGA OV -0.074; TCGA PAAD -0.161; TCGA STAD -0.14; TCGA UCEC -0.081 |
hsa-miR-125b-5p | MUC1 | 10 cancers: BRCA; CESC; COAD; ESCA; LIHC; OV; PRAD; SARC; STAD; UCEC | miRNAWalker2 validate | TCGA BRCA -0.231; TCGA CESC -0.2; TCGA COAD -0.247; TCGA ESCA -0.768; TCGA LIHC -0.423; TCGA OV -0.162; TCGA PRAD -0.244; TCGA SARC -0.656; TCGA STAD -0.386; TCGA UCEC -0.39 |
hsa-miR-125b-5p | NRARP | 9 cancers: BRCA; COAD; ESCA; HNSC; KIRC; LIHC; LUSC; PRAD; STAD | miRNAWalker2 validate | TCGA BRCA -0.17; TCGA COAD -0.215; TCGA ESCA -0.335; TCGA HNSC -0.197; TCGA KIRC -0.405; TCGA LIHC -0.136; TCGA LUSC -0.422; TCGA PRAD -0.141; TCGA STAD -0.206 |
hsa-miR-125b-5p | PLEKHA8 | 10 cancers: BRCA; CESC; ESCA; HNSC; LIHC; LUAD; LUSC; THCA; STAD; UCEC | miRNAWalker2 validate | TCGA BRCA -0.113; TCGA CESC -0.153; TCGA ESCA -0.109; TCGA HNSC -0.167; TCGA LIHC -0.138; TCGA LUAD -0.103; TCGA LUSC -0.28; TCGA THCA -0.192; TCGA STAD -0.126; TCGA UCEC -0.097 |
hsa-miR-125b-5p | PSMB1 | 13 cancers: BRCA; CESC; COAD; ESCA; HNSC; LGG; LIHC; LUSC; OV; PAAD; PRAD; STAD; UCEC | miRNAWalker2 validate | TCGA BRCA -0.094; TCGA CESC -0.074; TCGA COAD -0.101; TCGA ESCA -0.084; TCGA HNSC -0.099; TCGA LGG -0.13; TCGA LIHC -0.069; TCGA LUSC -0.119; TCGA OV -0.126; TCGA PAAD -0.143; TCGA PRAD -0.126; TCGA STAD -0.086; TCGA UCEC -0.102 |
hsa-miR-125b-5p | QSOX2 | 13 cancers: BRCA; CESC; COAD; ESCA; HNSC; KIRC; LGG; LIHC; LUAD; LUSC; PAAD; PRAD; STAD | miRNAWalker2 validate; miRNATAP | TCGA BRCA -0.1; TCGA CESC -0.106; TCGA COAD -0.061; TCGA ESCA -0.193; TCGA HNSC -0.136; TCGA KIRC -0.167; TCGA LGG -0.098; TCGA LIHC -0.112; TCGA LUAD -0.063; TCGA LUSC -0.188; TCGA PAAD -0.143; TCGA PRAD -0.163; TCGA STAD -0.181 |
hsa-miR-125b-5p | RFWD3 | 9 cancers: BRCA; COAD; HNSC; LGG; LIHC; LUAD; LUSC; PRAD; STAD | miRNAWalker2 validate | TCGA BRCA -0.086; TCGA COAD -0.093; TCGA HNSC -0.146; TCGA LGG -0.084; TCGA LIHC -0.166; TCGA LUAD -0.116; TCGA LUSC -0.21; TCGA PRAD -0.149; TCGA STAD -0.174 |
hsa-miR-125b-5p | RNASEH2A | 13 cancers: BRCA; COAD; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; LUSC; PAAD; SARC; STAD; UCEC | miRNAWalker2 validate | TCGA BRCA -0.414; TCGA COAD -0.13; TCGA HNSC -0.093; TCGA KIRC -0.109; TCGA KIRP -0.117; TCGA LGG -0.217; TCGA LIHC -0.415; TCGA LUAD -0.104; TCGA LUSC -0.304; TCGA PAAD -0.386; TCGA SARC -0.141; TCGA STAD -0.171; TCGA UCEC -0.092 |
hsa-miR-125b-5p | RRP7A | 10 cancers: BRCA; COAD; ESCA; HNSC; LIHC; LUSC; OV; PAAD; STAD; UCEC | miRNAWalker2 validate; mirMAP | TCGA BRCA -0.119; TCGA COAD -0.084; TCGA ESCA -0.103; TCGA HNSC -0.163; TCGA LIHC -0.137; TCGA LUSC -0.13; TCGA OV -0.099; TCGA PAAD -0.284; TCGA STAD -0.062; TCGA UCEC -0.13 |
hsa-miR-125b-5p | SLC35A4 | 10 cancers: BRCA; COAD; ESCA; LGG; LIHC; OV; PAAD; SARC; THCA; STAD | miRNAWalker2 validate; MirTarget; miRNATAP | TCGA BRCA -0.061; TCGA COAD -0.078; TCGA ESCA -0.081; TCGA LGG -0.132; TCGA LIHC -0.062; TCGA OV -0.066; TCGA PAAD -0.085; TCGA SARC -0.075; TCGA THCA -0.171; TCGA STAD -0.055 |
hsa-miR-125b-5p | SMC2 | 12 cancers: BRCA; COAD; ESCA; LGG; LIHC; LUAD; LUSC; OV; PRAD; SARC; THCA; STAD | miRNAWalker2 validate | TCGA BRCA -0.088; TCGA COAD -0.157; TCGA ESCA -0.146; TCGA LGG -0.107; TCGA LIHC -0.203; TCGA LUAD -0.114; TCGA LUSC -0.223; TCGA OV -0.098; TCGA PRAD -0.254; TCGA SARC -0.131; TCGA THCA -0.11; TCGA STAD -0.315 |
hsa-miR-125b-5p | TIMM10 | 10 cancers: BRCA; COAD; ESCA; LGG; LUAD; LUSC; OV; PAAD; STAD; UCEC | miRNAWalker2 validate | TCGA BRCA -0.198; TCGA COAD -0.076; TCGA ESCA -0.156; TCGA LGG -0.142; TCGA LUAD -0.107; TCGA LUSC -0.183; TCGA OV -0.169; TCGA PAAD -0.148; TCGA STAD -0.072; TCGA UCEC -0.091 |
hsa-miR-125b-5p | EIF1AD | 12 cancers: BRCA; CESC; COAD; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; LUSC; OV; UCEC | MirTarget; miRNATAP | TCGA BRCA -0.092; TCGA CESC -0.07; TCGA COAD -0.059; TCGA HNSC -0.147; TCGA KIRC -0.054; TCGA KIRP -0.053; TCGA LGG -0.077; TCGA LIHC -0.108; TCGA LUAD -0.051; TCGA LUSC -0.143; TCGA OV -0.065; TCGA UCEC -0.054 |
hsa-miR-125b-5p | PSMB8 | 11 cancers: BRCA; COAD; ESCA; HNSC; KIRC; KIRP; LGG; OV; SARC; STAD; UCEC | MirTarget | TCGA BRCA -0.17; TCGA COAD -0.109; TCGA ESCA -0.173; TCGA HNSC -0.151; TCGA KIRC -0.34; TCGA KIRP -0.125; TCGA LGG -0.145; TCGA OV -0.231; TCGA SARC -0.166; TCGA STAD -0.122; TCGA UCEC -0.159 |
hsa-miR-125b-5p | CDR2L | 9 cancers: BRCA; CESC; ESCA; HNSC; KIRP; LUSC; OV; PRAD; UCEC | MirTarget; miRNATAP | TCGA BRCA -0.145; TCGA CESC -0.193; TCGA ESCA -0.434; TCGA HNSC -0.147; TCGA KIRP -0.136; TCGA LUSC -0.287; TCGA OV -0.287; TCGA PRAD -0.345; TCGA UCEC -0.169 |
hsa-miR-125b-5p | PMM2 | 15 cancers: BRCA; CESC; COAD; ESCA; HNSC; KIRC; LGG; LIHC; LUSC; OV; PAAD; PRAD; THCA; STAD; UCEC | MirTarget | TCGA BRCA -0.193; TCGA CESC -0.169; TCGA COAD -0.091; TCGA ESCA -0.237; TCGA HNSC -0.131; TCGA KIRC -0.196; TCGA LGG -0.121; TCGA LIHC -0.126; TCGA LUSC -0.126; TCGA OV -0.082; TCGA PAAD -0.242; TCGA PRAD -0.107; TCGA THCA -0.077; TCGA STAD -0.188; TCGA UCEC -0.184 |
hsa-miR-125b-5p | DPH2 | 16 cancers: BRCA; CESC; COAD; ESCA; HNSC; KIRP; LIHC; LUAD; LUSC; OV; PAAD; PRAD; SARC; THCA; STAD; UCEC | MirTarget | TCGA BRCA -0.153; TCGA CESC -0.15; TCGA COAD -0.069; TCGA ESCA -0.21; TCGA HNSC -0.092; TCGA KIRP -0.067; TCGA LIHC -0.259; TCGA LUAD -0.076; TCGA LUSC -0.186; TCGA OV -0.123; TCGA PAAD -0.116; TCGA PRAD -0.271; TCGA SARC -0.113; TCGA THCA -0.106; TCGA STAD -0.193; TCGA UCEC -0.091 |
hsa-miR-125b-5p | BRMS1 | 11 cancers: BRCA; CESC; ESCA; HNSC; LGG; LIHC; LUSC; OV; PAAD; STAD; UCEC | MirTarget | TCGA BRCA -0.252; TCGA CESC -0.11; TCGA ESCA -0.135; TCGA HNSC -0.267; TCGA LGG -0.138; TCGA LIHC -0.203; TCGA LUSC -0.168; TCGA OV -0.113; TCGA PAAD -0.216; TCGA STAD -0.084; TCGA UCEC -0.115 |
hsa-miR-125b-5p | TOR2A | 15 cancers: BRCA; CESC; COAD; ESCA; HNSC; KIRC; LGG; LIHC; LUSC; OV; PAAD; PRAD; THCA; STAD; UCEC | MirTarget; miRNATAP | TCGA BRCA -0.312; TCGA CESC -0.066; TCGA COAD -0.114; TCGA ESCA -0.293; TCGA HNSC -0.154; TCGA KIRC -0.085; TCGA LGG -0.199; TCGA LIHC -0.117; TCGA LUSC -0.178; TCGA OV -0.219; TCGA PAAD -0.299; TCGA PRAD -0.107; TCGA THCA -0.115; TCGA STAD -0.126; TCGA UCEC -0.128 |
hsa-miR-125b-5p | TRIM14 | 10 cancers: BRCA; COAD; ESCA; HNSC; KIRC; OV; PRAD; SARC; STAD; UCEC | MirTarget | TCGA BRCA -0.114; TCGA COAD -0.094; TCGA ESCA -0.133; TCGA HNSC -0.111; TCGA KIRC -0.384; TCGA OV -0.145; TCGA PRAD -0.23; TCGA SARC -0.284; TCGA STAD -0.133; TCGA UCEC -0.117 |
hsa-miR-125b-5p | B3GALNT2 | 10 cancers: BRCA; COAD; HNSC; LIHC; LUAD; LUSC; PAAD; SARC; THCA; STAD | MirTarget | TCGA BRCA -0.099; TCGA COAD -0.072; TCGA HNSC -0.062; TCGA LIHC -0.194; TCGA LUAD -0.144; TCGA LUSC -0.108; TCGA PAAD -0.106; TCGA SARC -0.179; TCGA THCA -0.222; TCGA STAD -0.073 |
hsa-miR-125b-5p | DCAF10 | 9 cancers: BRCA; CESC; HNSC; LUAD; LUSC; PRAD; SARC; THCA; STAD | MirTarget | TCGA BRCA -0.117; TCGA CESC -0.061; TCGA HNSC -0.105; TCGA LUAD -0.114; TCGA LUSC -0.125; TCGA PRAD -0.121; TCGA SARC -0.072; TCGA THCA -0.092; TCGA STAD -0.064 |
hsa-miR-125b-5p | CDK16 | 10 cancers: BRCA; COAD; LIHC; LUAD; LUSC; OV; PAAD; PRAD; STAD; UCEC | MirTarget; miRNATAP | TCGA BRCA -0.163; TCGA COAD -0.083; TCGA LIHC -0.28; TCGA LUAD -0.1; TCGA LUSC -0.117; TCGA OV -0.11; TCGA PAAD -0.164; TCGA PRAD -0.065; TCGA STAD -0.118; TCGA UCEC -0.086 |
hsa-miR-125b-5p | CIAPIN1 | 13 cancers: BRCA; CESC; COAD; HNSC; LGG; LIHC; LUAD; LUSC; OV; PRAD; THCA; STAD; UCEC | MirTarget | TCGA BRCA -0.086; TCGA CESC -0.056; TCGA COAD -0.078; TCGA HNSC -0.179; TCGA LGG -0.165; TCGA LIHC -0.088; TCGA LUAD -0.061; TCGA LUSC -0.079; TCGA OV -0.09; TCGA PRAD -0.115; TCGA THCA -0.183; TCGA STAD -0.078; TCGA UCEC -0.058 |
hsa-miR-125b-5p | SCLY | 9 cancers: BRCA; COAD; ESCA; KIRP; LGG; LUAD; SARC; STAD; UCEC | MirTarget | TCGA BRCA -0.187; TCGA COAD -0.118; TCGA ESCA -0.172; TCGA KIRP -0.077; TCGA LGG -0.212; TCGA LUAD -0.1; TCGA SARC -0.099; TCGA STAD -0.083; TCGA UCEC -0.06 |
hsa-miR-125b-5p | SYVN1 | 9 cancers: BRCA; CESC; ESCA; HNSC; KIRC; PAAD; PRAD; THCA; UCEC | MirTarget; miRNATAP | TCGA BRCA -0.125; TCGA CESC -0.095; TCGA ESCA -0.068; TCGA HNSC -0.06; TCGA KIRC -0.113; TCGA PAAD -0.177; TCGA PRAD -0.063; TCGA THCA -0.112; TCGA UCEC -0.073 |
hsa-miR-125b-5p | COPS7B | 9 cancers: BRCA; ESCA; KIRP; LGG; LIHC; LUAD; LUSC; PAAD; STAD | MirTarget; miRNATAP | TCGA BRCA -0.077; TCGA ESCA -0.064; TCGA KIRP -0.097; TCGA LGG -0.127; TCGA LIHC -0.194; TCGA LUAD -0.072; TCGA LUSC -0.081; TCGA PAAD -0.166; TCGA STAD -0.065 |
hsa-miR-125b-5p | PSMG3 | 12 cancers: BRCA; CESC; COAD; ESCA; HNSC; LGG; LIHC; LUAD; LUSC; PAAD; STAD; UCEC | MirTarget | TCGA BRCA -0.251; TCGA CESC -0.086; TCGA COAD -0.091; TCGA ESCA -0.124; TCGA HNSC -0.099; TCGA LGG -0.151; TCGA LIHC -0.287; TCGA LUAD -0.081; TCGA LUSC -0.225; TCGA PAAD -0.454; TCGA STAD -0.146; TCGA UCEC -0.114 |
hsa-miR-125b-5p | USP37 | 9 cancers: BRCA; ESCA; KIRC; KIRP; LIHC; LUAD; PRAD; SARC; STAD | MirTarget; miRNATAP | TCGA BRCA -0.065; TCGA ESCA -0.124; TCGA KIRC -0.103; TCGA KIRP -0.073; TCGA LIHC -0.158; TCGA LUAD -0.232; TCGA PRAD -0.12; TCGA SARC -0.147; TCGA STAD -0.189 |
hsa-miR-125b-5p | TRIAP1 | 13 cancers: BRCA; COAD; ESCA; KIRC; KIRP; LGG; LUAD; LUSC; PAAD; PRAD; THCA; STAD; UCEC | MirTarget; miRNATAP | TCGA BRCA -0.072; TCGA COAD -0.092; TCGA ESCA -0.117; TCGA KIRC -0.057; TCGA KIRP -0.064; TCGA LGG -0.193; TCGA LUAD -0.107; TCGA LUSC -0.071; TCGA PAAD -0.183; TCGA PRAD -0.055; TCGA THCA -0.053; TCGA STAD -0.139; TCGA UCEC -0.061 |
hsa-miR-125b-5p | TXNRD1 | 11 cancers: BRCA; CESC; COAD; LIHC; LUAD; LUSC; PRAD; SARC; THCA; STAD; UCEC | MirTarget; miRNATAP | TCGA BRCA -0.056; TCGA CESC -0.12; TCGA COAD -0.108; TCGA LIHC -0.233; TCGA LUAD -0.195; TCGA LUSC -0.508; TCGA PRAD -0.178; TCGA SARC -0.227; TCGA THCA -0.362; TCGA STAD -0.139; TCGA UCEC -0.135 |
hsa-miR-125b-5p | PDIA3 | 12 cancers: BRCA; CESC; COAD; ESCA; HNSC; KIRC; LIHC; LUAD; PAAD; PRAD; STAD; UCEC | MirTarget | TCGA BRCA -0.173; TCGA CESC -0.066; TCGA COAD -0.089; TCGA ESCA -0.199; TCGA HNSC -0.101; TCGA KIRC -0.095; TCGA LIHC -0.115; TCGA LUAD -0.161; TCGA PAAD -0.148; TCGA PRAD -0.091; TCGA STAD -0.159; TCGA UCEC -0.102 |
hsa-miR-125b-5p | RAB3D | 13 cancers: BRCA; CESC; COAD; HNSC; KIRC; KIRP; LIHC; LUAD; LUSC; PAAD; PRAD; SARC; UCEC | MirTarget; miRNATAP | TCGA BRCA -0.221; TCGA CESC -0.079; TCGA COAD -0.07; TCGA HNSC -0.199; TCGA KIRC -0.224; TCGA KIRP -0.279; TCGA LIHC -0.473; TCGA LUAD -0.129; TCGA LUSC -0.138; TCGA PAAD -0.29; TCGA PRAD -0.113; TCGA SARC -0.21; TCGA UCEC -0.098 |
hsa-miR-125b-5p | WDR5 | 11 cancers: BRCA; CESC; COAD; ESCA; HNSC; LIHC; LUSC; OV; PAAD; PRAD; STAD | MirTarget | TCGA BRCA -0.144; TCGA CESC -0.066; TCGA COAD -0.065; TCGA ESCA -0.123; TCGA HNSC -0.06; TCGA LIHC -0.119; TCGA LUSC -0.26; TCGA OV -0.07; TCGA PAAD -0.234; TCGA PRAD -0.054; TCGA STAD -0.15 |
hsa-miR-125b-5p | DDX54 | 11 cancers: BRCA; CESC; COAD; ESCA; HNSC; LGG; LIHC; LUSC; PAAD; STAD; UCEC | MirTarget | TCGA BRCA -0.181; TCGA CESC -0.057; TCGA COAD -0.055; TCGA ESCA -0.132; TCGA HNSC -0.06; TCGA LGG -0.127; TCGA LIHC -0.104; TCGA LUSC -0.194; TCGA PAAD -0.245; TCGA STAD -0.115; TCGA UCEC -0.065 |
hsa-miR-125b-5p | LASP1 | 10 cancers: BRCA; CESC; COAD; ESCA; HNSC; KIRC; KIRP; LGG; LIHC; STAD | mirMAP | TCGA BRCA -0.171; TCGA CESC -0.109; TCGA COAD -0.057; TCGA ESCA -0.283; TCGA HNSC -0.07; TCGA KIRC -0.056; TCGA KIRP -0.08; TCGA LGG -0.118; TCGA LIHC -0.243; TCGA STAD -0.095 |
hsa-miR-125b-5p | POLR1A | 9 cancers: BRCA; CESC; ESCA; HNSC; LIHC; LUSC; PRAD; THCA; STAD | mirMAP | TCGA BRCA -0.07; TCGA CESC -0.141; TCGA ESCA -0.119; TCGA HNSC -0.179; TCGA LIHC -0.155; TCGA LUSC -0.102; TCGA PRAD -0.126; TCGA THCA -0.073; TCGA STAD -0.11 |
hsa-miR-125b-5p | ITPK1 | 10 cancers: BRCA; CESC; COAD; ESCA; HNSC; LGG; LUSC; PAAD; SARC; UCEC | mirMAP | TCGA BRCA -0.169; TCGA CESC -0.075; TCGA COAD -0.092; TCGA ESCA -0.271; TCGA HNSC -0.152; TCGA LGG -0.091; TCGA LUSC -0.149; TCGA PAAD -0.12; TCGA SARC -0.254; TCGA UCEC -0.128 |
hsa-miR-125b-5p | PYCRL | 11 cancers: BRCA; CESC; COAD; ESCA; HNSC; LIHC; LUSC; OV; PAAD; STAD; UCEC | mirMAP | TCGA BRCA -0.424; TCGA CESC -0.123; TCGA COAD -0.13; TCGA ESCA -0.238; TCGA HNSC -0.184; TCGA LIHC -0.213; TCGA LUSC -0.191; TCGA OV -0.237; TCGA PAAD -0.436; TCGA STAD -0.135; TCGA UCEC -0.085 |
hsa-miR-125b-5p | MLEC | 11 cancers: BRCA; CESC; COAD; ESCA; KIRC; LIHC; LUAD; PAAD; PRAD; THCA; STAD | mirMAP | TCGA BRCA -0.072; TCGA CESC -0.104; TCGA COAD -0.105; TCGA ESCA -0.343; TCGA KIRC -0.182; TCGA LIHC -0.122; TCGA LUAD -0.169; TCGA PAAD -0.122; TCGA PRAD -0.141; TCGA THCA -0.321; TCGA STAD -0.203 |
hsa-miR-125b-5p | SLC12A7 | 10 cancers: BRCA; ESCA; KIRC; LIHC; OV; PAAD; PRAD; THCA; STAD; UCEC | mirMAP | TCGA BRCA -0.178; TCGA ESCA -0.208; TCGA KIRC -0.248; TCGA LIHC -0.178; TCGA OV -0.097; TCGA PAAD -0.16; TCGA PRAD -0.082; TCGA THCA -0.109; TCGA STAD -0.183; TCGA UCEC -0.132 |
hsa-miR-125b-5p | NCLN | 13 cancers: BRCA; CESC; COAD; ESCA; HNSC; KIRP; LGG; LIHC; LUSC; OV; PAAD; STAD; UCEC | mirMAP | TCGA BRCA -0.228; TCGA CESC -0.095; TCGA COAD -0.101; TCGA ESCA -0.224; TCGA HNSC -0.199; TCGA KIRP -0.059; TCGA LGG -0.182; TCGA LIHC -0.088; TCGA LUSC -0.128; TCGA OV -0.064; TCGA PAAD -0.378; TCGA STAD -0.155; TCGA UCEC -0.102 |
hsa-miR-125b-5p | KLF16 | 11 cancers: BRCA; CESC; COAD; ESCA; HNSC; KIRP; LIHC; LUSC; PAAD; STAD; UCEC | mirMAP; miRNATAP | TCGA BRCA -0.287; TCGA CESC -0.092; TCGA COAD -0.074; TCGA ESCA -0.161; TCGA HNSC -0.082; TCGA KIRP -0.099; TCGA LIHC -0.108; TCGA LUSC -0.235; TCGA PAAD -0.216; TCGA STAD -0.131; TCGA UCEC -0.085 |
hsa-miR-125b-5p | CENPO | 14 cancers: BRCA; CESC; COAD; ESCA; HNSC; LGG; LIHC; LUAD; LUSC; PAAD; PRAD; THCA; STAD; UCEC | mirMAP | TCGA BRCA -0.254; TCGA CESC -0.127; TCGA COAD -0.142; TCGA ESCA -0.204; TCGA HNSC -0.142; TCGA LGG -0.149; TCGA LIHC -0.428; TCGA LUAD -0.132; TCGA LUSC -0.265; TCGA PAAD -0.237; TCGA PRAD -0.27; TCGA THCA -0.094; TCGA STAD -0.107; TCGA UCEC -0.111 |
hsa-miR-125b-5p | RFT1 | 10 cancers: BRCA; CESC; COAD; ESCA; HNSC; LIHC; LUSC; OV; PAAD; STAD | mirMAP | TCGA BRCA -0.059; TCGA CESC -0.085; TCGA COAD -0.086; TCGA ESCA -0.151; TCGA HNSC -0.064; TCGA LIHC -0.161; TCGA LUSC -0.102; TCGA OV -0.057; TCGA PAAD -0.161; TCGA STAD -0.1 |
hsa-miR-125b-5p | SLC27A4 | 11 cancers: BRCA; CESC; COAD; ESCA; HNSC; LUSC; OV; PAAD; THCA; STAD; UCEC | mirMAP; miRNATAP | TCGA BRCA -0.265; TCGA CESC -0.13; TCGA COAD -0.094; TCGA ESCA -0.247; TCGA HNSC -0.305; TCGA LUSC -0.295; TCGA OV -0.126; TCGA PAAD -0.249; TCGA THCA -0.602; TCGA STAD -0.091; TCGA UCEC -0.131 |
hsa-miR-125b-5p | GMPPB | 10 cancers: BRCA; COAD; ESCA; LIHC; OV; PAAD; SARC; THCA; STAD; UCEC | mirMAP | TCGA BRCA -0.235; TCGA COAD -0.107; TCGA ESCA -0.259; TCGA LIHC -0.076; TCGA OV -0.1; TCGA PAAD -0.164; TCGA SARC -0.095; TCGA THCA -0.237; TCGA STAD -0.13; TCGA UCEC -0.109 |
hsa-miR-125b-5p | LMNB2 | 10 cancers: BRCA; COAD; ESCA; HNSC; KIRP; LIHC; LUSC; PAAD; PRAD; STAD | mirMAP | TCGA BRCA -0.3; TCGA COAD -0.11; TCGA ESCA -0.132; TCGA HNSC -0.126; TCGA KIRP -0.104; TCGA LIHC -0.353; TCGA LUSC -0.236; TCGA PAAD -0.2; TCGA PRAD -0.103; TCGA STAD -0.212 |
hsa-miR-125b-5p | EPHA10 | 9 cancers: BRCA; CESC; COAD; ESCA; KIRP; LGG; LIHC; OV; STAD | mirMAP; miRNATAP | TCGA BRCA -0.418; TCGA CESC -0.349; TCGA COAD -0.127; TCGA ESCA -0.683; TCGA KIRP -0.495; TCGA LGG -0.346; TCGA LIHC -0.639; TCGA OV -0.374; TCGA STAD -0.149 |
hsa-miR-125b-5p | TMEM120B | 10 cancers: BRCA; CESC; COAD; KIRP; LIHC; LUAD; LUSC; PAAD; PRAD; THCA | mirMAP; miRNATAP | TCGA BRCA -0.106; TCGA CESC -0.128; TCGA COAD -0.071; TCGA KIRP -0.073; TCGA LIHC -0.325; TCGA LUAD -0.096; TCGA LUSC -0.091; TCGA PAAD -0.331; TCGA PRAD -0.086; TCGA THCA -0.129 |
hsa-miR-125b-5p | NIPA1 | 14 cancers: BRCA; CESC; COAD; ESCA; HNSC; KIRC; LIHC; LUAD; LUSC; PRAD; SARC; THCA; STAD; UCEC | miRNATAP | TCGA BRCA -0.177; TCGA CESC -0.057; TCGA COAD -0.128; TCGA ESCA -0.174; TCGA HNSC -0.112; TCGA KIRC -0.081; TCGA LIHC -0.159; TCGA LUAD -0.104; TCGA LUSC -0.209; TCGA PRAD -0.162; TCGA SARC -0.269; TCGA THCA -0.206; TCGA STAD -0.189; TCGA UCEC -0.139 |
hsa-miR-125b-5p | UBE2W | 10 cancers: BRCA; COAD; HNSC; LUAD; OV; PRAD; SARC; THCA; STAD; UCEC | miRNATAP | TCGA BRCA -0.082; TCGA COAD -0.071; TCGA HNSC -0.124; TCGA LUAD -0.209; TCGA OV -0.118; TCGA PRAD -0.149; TCGA SARC -0.095; TCGA THCA -0.073; TCGA STAD -0.12; TCGA UCEC -0.072 |
hsa-miR-125b-5p | MAP3K11 | 9 cancers: BRCA; COAD; ESCA; HNSC; KIRC; OV; PAAD; STAD; UCEC | miRNATAP | TCGA BRCA -0.128; TCGA COAD -0.065; TCGA ESCA -0.129; TCGA HNSC -0.128; TCGA KIRC -0.191; TCGA OV -0.058; TCGA PAAD -0.188; TCGA STAD -0.062; TCGA UCEC -0.083 |
hsa-miR-125b-5p | NEU1 | 12 cancers: BRCA; CESC; ESCA; HNSC; KIRC; LGG; LIHC; LUAD; OV; PAAD; THCA; UCEC | miRNATAP | TCGA BRCA -0.221; TCGA CESC -0.16; TCGA ESCA -0.205; TCGA HNSC -0.132; TCGA KIRC -0.104; TCGA LGG -0.108; TCGA LIHC -0.323; TCGA LUAD -0.17; TCGA OV -0.222; TCGA PAAD -0.213; TCGA THCA -0.165; TCGA UCEC -0.211 |
hsa-miR-125b-5p | TAZ | 10 cancers: BRCA; ESCA; KIRC; KIRP; LGG; LIHC; LUSC; OV; PAAD; UCEC | miRNATAP | TCGA BRCA -0.138; TCGA ESCA -0.089; TCGA KIRC -0.162; TCGA KIRP -0.085; TCGA LGG -0.113; TCGA LIHC -0.189; TCGA LUSC -0.228; TCGA OV -0.089; TCGA PAAD -0.251; TCGA UCEC -0.102 |
hsa-miR-125b-5p | TMED9 | 11 cancers: BRCA; CESC; ESCA; HNSC; KIRC; KIRP; LIHC; OV; PAAD; THCA; UCEC | miRNATAP | TCGA BRCA -0.223; TCGA CESC -0.06; TCGA ESCA -0.12; TCGA HNSC -0.081; TCGA KIRC -0.138; TCGA KIRP -0.057; TCGA LIHC -0.175; TCGA OV -0.111; TCGA PAAD -0.252; TCGA THCA -0.083; TCGA UCEC -0.08 |
hsa-miR-125b-5p | GOLGA5 | 14 cancers: BRCA; CESC; COAD; ESCA; HNSC; LGG; LUAD; LUSC; OV; PRAD; SARC; THCA; STAD; UCEC | miRNATAP | TCGA BRCA -0.094; TCGA CESC -0.074; TCGA COAD -0.066; TCGA ESCA -0.077; TCGA HNSC -0.124; TCGA LGG -0.055; TCGA LUAD -0.131; TCGA LUSC -0.147; TCGA OV -0.078; TCGA PRAD -0.063; TCGA SARC -0.064; TCGA THCA -0.097; TCGA STAD -0.101; TCGA UCEC -0.072 |
hsa-miR-125b-5p | SET | 10 cancers: BRCA; COAD; ESCA; HNSC; LGG; LIHC; LUAD; LUSC; PRAD; STAD | miRNATAP | TCGA BRCA -0.09; TCGA COAD -0.089; TCGA ESCA -0.094; TCGA HNSC -0.106; TCGA LGG -0.075; TCGA LIHC -0.138; TCGA LUAD -0.093; TCGA LUSC -0.209; TCGA PRAD -0.136; TCGA STAD -0.142 |
hsa-miR-125b-5p | KCTD5 | 9 cancers: BRCA; CESC; COAD; ESCA; HNSC; LGG; LUSC; PRAD; STAD | miRNATAP | TCGA BRCA -0.191; TCGA CESC -0.065; TCGA COAD -0.103; TCGA ESCA -0.164; TCGA HNSC -0.159; TCGA LGG -0.156; TCGA LUSC -0.135; TCGA PRAD -0.116; TCGA STAD -0.147 |
hsa-miR-125b-5p | SEC24A | 11 cancers: CESC; COAD; ESCA; HNSC; KIRC; LGG; LUAD; PRAD; THCA; STAD; UCEC | miRNAWalker2 validate | TCGA CESC -0.116; TCGA COAD -0.067; TCGA ESCA -0.212; TCGA HNSC -0.138; TCGA KIRC -0.087; TCGA LGG -0.09; TCGA LUAD -0.118; TCGA PRAD -0.149; TCGA THCA -0.164; TCGA STAD -0.15; TCGA UCEC -0.117 |
hsa-miR-125b-5p | SLC7A1 | 12 cancers: CESC; ESCA; HNSC; KIRC; LGG; LIHC; LUAD; LUSC; PAAD; SARC; THCA; STAD | miRNAWalker2 validate; MirTarget; miRNATAP | TCGA CESC -0.1; TCGA ESCA -0.15; TCGA HNSC -0.203; TCGA KIRC -0.14; TCGA LGG -0.124; TCGA LIHC -0.549; TCGA LUAD -0.093; TCGA LUSC -0.177; TCGA PAAD -0.134; TCGA SARC -0.137; TCGA THCA -0.275; TCGA STAD -0.205 |
hsa-miR-125b-5p | SSR3 | 10 cancers: CESC; COAD; ESCA; HNSC; LIHC; LUAD; OV; PRAD; STAD; UCEC | miRNAWalker2 validate | TCGA CESC -0.137; TCGA COAD -0.105; TCGA ESCA -0.08; TCGA HNSC -0.154; TCGA LIHC -0.147; TCGA LUAD -0.086; TCGA OV -0.106; TCGA PRAD -0.072; TCGA STAD -0.112; TCGA UCEC -0.058 |
hsa-miR-125b-5p | TMEM2 | 10 cancers: CESC; ESCA; HNSC; KIRC; LUAD; OV; PRAD; THCA; STAD; UCEC | miRNAWalker2 validate | TCGA CESC -0.16; TCGA ESCA -0.451; TCGA HNSC -0.098; TCGA KIRC -0.352; TCGA LUAD -0.083; TCGA OV -0.161; TCGA PRAD -0.272; TCGA THCA -0.123; TCGA STAD -0.219; TCGA UCEC -0.128 |
hsa-miR-125b-5p | CRIPT | 9 cancers: CESC; COAD; KIRP; LIHC; LUAD; LUSC; OV; PRAD; UCEC | MirTarget | TCGA CESC -0.073; TCGA COAD -0.055; TCGA KIRP -0.053; TCGA LIHC -0.054; TCGA LUAD -0.189; TCGA LUSC -0.163; TCGA OV -0.1; TCGA PRAD -0.092; TCGA UCEC -0.054 |
hsa-miR-125b-5p | PCSK7 | 9 cancers: CESC; COAD; ESCA; HNSC; KIRC; LGG; LIHC; SARC; UCEC | MirTarget; miRNATAP | TCGA CESC -0.073; TCGA COAD -0.084; TCGA ESCA -0.312; TCGA HNSC -0.055; TCGA KIRC -0.117; TCGA LGG -0.098; TCGA LIHC -0.083; TCGA SARC -0.142; TCGA UCEC -0.078 |
hsa-miR-125b-5p | PCTP | 9 cancers: CESC; ESCA; KIRP; LUAD; OV; PAAD; PRAD; THCA; UCEC | MirTarget; miRNATAP | TCGA CESC -0.159; TCGA ESCA -0.24; TCGA KIRP -0.104; TCGA LUAD -0.222; TCGA OV -0.377; TCGA PAAD -0.148; TCGA PRAD -0.255; TCGA THCA -0.149; TCGA UCEC -0.171 |
hsa-miR-125b-5p | UBE2G1 | 12 cancers: CESC; COAD; HNSC; KIRP; LGG; LUAD; LUSC; PAAD; PRAD; SARC; THCA; STAD | MirTarget; miRNATAP | TCGA CESC -0.053; TCGA COAD -0.066; TCGA HNSC -0.085; TCGA KIRP -0.069; TCGA LGG -0.053; TCGA LUAD -0.062; TCGA LUSC -0.18; TCGA PAAD -0.085; TCGA PRAD -0.127; TCGA SARC -0.076; TCGA THCA -0.136; TCGA STAD -0.07 |
hsa-miR-125b-5p | TIAL1 | 9 cancers: COAD; KIRC; KIRP; LGG; LUAD; LUSC; PAAD; PRAD; STAD | RAID | TCGA COAD -0.065; TCGA KIRC -0.069; TCGA KIRP -0.081; TCGA LGG -0.159; TCGA LUAD -0.116; TCGA LUSC -0.153; TCGA PAAD -0.094; TCGA PRAD -0.108; TCGA STAD -0.098 |
hsa-miR-125b-5p | STC2 | 9 cancers: HNSC; KIRC; LGG; LIHC; LUSC; PRAD; SARC; THCA; UCEC | miRNAWalker2 validate | TCGA HNSC -0.445; TCGA KIRC -1.192; TCGA LGG -0.728; TCGA LIHC -0.48; TCGA LUSC -0.49; TCGA PRAD -0.248; TCGA SARC -0.302; TCGA THCA -0.384; TCGA UCEC -0.218 |
Enriched cancer pathways of putative targets